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ABSTRACT OF DISSERTATION

ELUCIDATING BINDING, FUSION AND ENTRY OF HUMAN METAPNEUMOVIRUS
Human metapneumovirus (HMPV) is a respiratory pathogen in the Paramyxoviridae family that
infects nearly 100% of the world population. This enveloped RNA virus causes severe viral
respiratory disease in infants, the elderly, and immunocompromised patients worldwide. Despite
its prevalence and importance to human health, no therapies are available against this pathogen.
Entry of paramyxoviruses into host cells generally requires the coordinated activity of the
attachment glycoprotein, G, which interacts with a cell receptor, and the fusion glycoprotein, F,
which promotes subsequent fusion of viral and cellular membranes. However, HMPV F is the
primary viral protein mediating both binding and fusion for HMPV. Previous work that showed
HMPV F mediates attachment to heparan sulfate proteoglycans (HSPGs), and some HMPV F fusion
activity can be promoted by acidic pH. The work presented here provides significant advances in
our understanding of the fusion and binding events during HMPV infection. We demonstrated
that low pH promotes fusion in HMPV F proteins from diverse clades, challenging previously
reported requirements and identifying a critical residue that enhances low pH promoted fusion.
These results support our hypothesis that electrostatic interactions play a key role in HMPV F
triggering and further elucidate the complexity of viral fusion proteins. Additionally, we
characterized the key features of the binding interaction between HMPV and HSPGs using
heparan sulfate mimetics, identifying an important sulfate modification, and demonstrated that
these interactions occur at the apical surface of polarized airways tissues. We identified
differences in particle binding related to the presence or absence of the HMPV G and SH
glycoproteins. Lastly, we characterized paramyxovirus infection in cystic fibrosis bronchial
epithelial cells, identifying a potential specific susceptibility to HMPV infection in these
individuals. The work presented here contributes to our understanding of HMPV infection, from
mechanisms of early events of entry to clinical scenarios.
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Chapter 1: Introduction
Paramyxoviruses: an overview
Paramyxoviruses are a large family of viruses that cause infections which are a
tremendous burden in human and animal worldwide. Paramyxoviruses are primarily spread by
aerosols. This family includes a number of human pathogens with effective vaccines available,
including the measles (MeV) and mumps (MuV) viruses. MeV was a leading cause of childhood
death from infectious diseases, causing an estimated 7-8 million deaths per year, until the
development of the measles vaccine in the 1960s. However, despite the initiative of the World
Health Organization (WHO), approximately 114,900 people died from MeV infection in 2014 –
mostly children under the age of 5 (reported by the WHO). MuV was also a common cause of viral
infection during childhood, resulting in serious lifelong complications from initial infection, until
the introduction of an effective vaccine in the 1960s. However, the spread of vaccination
noncompliance in developed countries, such as the United States, has led to a re-emergence of
these viruses in populations where they had been nearly eradicated (1). The paramyxovirus family
also includes viruses that are leading causes of respiratory diseases in humans that currently do
not have vaccines available. Respiratory syncytial virus (RSV) is the leading cause of respiratory
infection in young children worldwide (2, 3). RSV infection is the second largest cause of mortality,
after malaria, in infants and causes up to 200,000 deaths per year worldwide and is the leading
cause of hospitalization in early childhood in developed nations (4, 5). Closely related to RSV,
human metapneumovirus (HMPV), is also recognized as a common causes of viral infection,
causing severe respiratory infections in susceptible individuals and is described in more detail in
this chapter. Respiratory infections in humans are also caused by paramyxoviruses parainfluenza
virus (PIV) types 1-3, which can cause significant disease in immunocompromised patients
undergoing organ transplant (6, 7). PIV1 is associated with croup in children (8). Additionally,
paramyxoviruses include several emerging zoonotic pathogens, Nipah (NiV) and Hendra (HeV)
viruses, transmitted by fruit bats in the Pteropodidae family (9, 10). HeV was identified in 1994 as
the causative agent of respiratory disease and febrile illness in horses and humans (11). Since its
discovery there have been seven human infections of HeV, of which four were fatal (57%) (12).
Furthermore, fatality in horses is nearly 70% from HeV infection (12). Outbreaks of NiV infection
in humans from infected pigs have been identified in Malaysia, Singapore, Bangladesh and India
since 1998, and have caused fatal encephalitis and mortality rates ranging from 43% to 100% (1215). In addition to infection in horses and pigs by the Henipaviruses, Hev and NiV, respectively,
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paramyxoviruses also cause disease in other species. Parainfluenza virus 5 (PIV5), formerly called
simian virus 5, can cause kennel cough in dogs and infect other animals (16-18). Sendai virus (SeV)
is responsible for a highly transmissible respiratory tract infection in mice, hamsters, guinea pigs,
rats, and occasionally pigs (19). Newcastle disease virus (NDV) (20) and avian metapneumovirus
(AMPV) (21) cause respiratory disease in domestic fowl, and bovine RSV causes respiratory illness
in cattle (22), and atlantic salmon paramyxovirus (ASP) in fish (23), leading to huge economic
losses in poultry and livestock industries.
All paramyxoviruses are enveloped, negative sense, single-stranded RNA viruses (24).
Based on morphological characteristics, protein function, and sequence homology, this large
family of approximately 36 species of diverse viruses is divided into 18 distinct genera, which are
grouped into two subfamilies, paramyxoviridae and pneumovirinae (Fig. 1). The pneumovirinae
subfamily consists of two genera, which include RSV and HMPV. The remaining genera are
classified in the paramyxoviridae subfamily, and include the viruses: MeV, MuV, PIV, HeV, NiV,
NDV, ASP, and reptilian viruses in the ferlaviruses genus (Fig. 1) (25-27). Several recently
discovered paramyxoviruses such as J virus, Mossman virus, and Salem virus have not yet been
classified within a subfamily (24).
Human metapneumovirus discovery and clinical relevance
HMPV is a ubiquitous pathogen that causes respiratory disease worldwide (28-30). HMPV
was first identified in 2001 in the Netherlands from nasopharyngeal aspirates of sick children (31).
Since its identification, HMPV is now known to be the cause of respiratory infections in humans
since at least 1958 (31). HMPV strains have been phylogenetically classified into two genetic
lineages (A and B) with distinct sublineages (A1, A2, B1, and B2) (32). While concurrent circulation
of all four subtypes is common, a single, usually different, subtype usually predominates each year
(33-36).
Nearly every person is exposed to HMPV in the first decade of life; sero-conversion occurs
on average by the age of five and nearly 100% of individuals test seropositive for antibody
reactivity to HMPV antigens by age ten (7). HMPV is the second most common cause of lower
respiratory infection in children, following the closely related respiratory syncytial virus (RSV) (37,
38). Importantly, up to 70% of infants hospitalized for severe RSV bronchiolitis were also coinfected with HMPV, suggesting HMPV co-infection leads to more severe disease during RSV
infection (39-41). Prematurity is a risk factor for developing severe illness from HMPV later in
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childhood, more so than for RSV illness (42). While infants are considered the most vulnerable
population to developing illness from HMPV, adults can foster severe respiratory infection as well,
especially elderly and immunocompromised patients (43-45). Even previously healthy adults can
develop severe respiratory disease that requires hospitalization (46). Long-term care residents
over the age of 65 are particularly at risk, as HMPV can cause illness in as many as 72% of patients
during outbreaks (47-49). Individuals with congenital heart defects are also at high risk of
developing severe disease (38, 50, 51). Furthermore, one study found the burden of
hospitalization for HMPV associated respiratory disease was 5.4 fold greater in HIV-infected
compared to HIV-uninfected children (52). Also HIV-infected children had greater bacterial
coinfection and a higher mortality rate than did uninfected children due to HMPV respiratory
infection (52). One study showed that children with cancer had a nearly 50% rate of
hospitalization due to HMPV infection (53). Individuals with chronic respiratory diseases, such as
chronic obstructive pulmonary disease and asthma, are also at risk for serious disease from HMPV
infection (54, 55). HMPV infection is also thought to be a significant cause of exacerbations and
pulmonary decline in individuals with cystic fibrosis (56-58). However it is not known how the
pathophysiology that results in cystic fibrosis promotes HMPV infection.
Most viral respiratory infections in healthy adults are contained in the upper respiratory
tract, resulting in symptoms associated with the ears, nose, throat, and sinuses. These symptoms
are often grouped together in association as the “common cold”, although there are numerous
distinct viruses that can cause this, including HMPV. However, respiratory infection can spread to
the lower respiratory tract, causing more severe disease. Complications of respiratory infection
associated with HMPV include pneumonia, bronchiolitis, and febrile seizures (44, 59). Such
complications can be life threatening in susceptible individuals. It has also been suggested that
severe acute respiratory infection from HMPV may have lifelong consequences such as asthma
and hyperresponsiveness of the airway (60, 61). While HMPV infection has been thought to be
restricted to the respiratory epithelium and lungs, there have been several reports of fatal
encephalitis with HMPV the only detected pathogen in both lung and brain tissue (62-64). There
are several other paramyxoviruses that are known to cause neurological disease in humans,
including measles (65, 66) and Nipah virus (14, 67, 68). Furthermore, HMPV infection has been
associated with acute myocarditis, or swelling of the heart myocardium commonly caused by viral
infection (69). Heart involvement has also been documented for mumps virus and human
parainfluenza viruses 2 and 3 (70). It is not known what viral or host genetic factors contribute to
3

HMPV tropism outside of the respiratory tract. Even though primary infection occurs during
childhood in the majority of cases, repeat infections are common throughout life, likely due to
strain variations and incomplete immunity. Despite HMPV prevalence and clinical relevance, there
are no specific antiviral treatments or vaccines available.
Paramyxovirus structure and the functions of surface glycoproteins
The genome of paramyxoviruses consists of six to ten genes and varies in size from 13 to
19 kb (71). The viral envelope, derived from the plasma membrane of the host, surrounds the
single-stranded RNA genome, contained within the nucleocapsid. The nucleocapsid is composed
of the nucleocapsid protein (N), the phosphoprotein (P) and the large polymerase protein (L). Of
the six to ten genes, only two or three of encoded proteins are expressed at the surface of the
virus. The surface glycoproteins are available to interact with the target cell during entry and serve
functions in attachment and membrane fusion to deliver the nucleocapsid to the cytoplasm. The
matrix protein (M) functions in particle assembly and is thought to be closely associated with the
viral membrane, surface glycoproteins, and nucleocapsid. The rest of the encoded proteins are
primarily involved in viral genome transcription, replication, or assembly. Some reptilian viruses,
including Fer-de-Lance virus, in the Ferlavirus genus have an additional gene encoding the
unknown protein (U) of approximately 20 kDa that has no counterpart in other paramyxoviruses
or any similarity to other reporter sequences (26, 27, 72). The order of genes in the genome of
HMPV is as follows: HMPV (3’-N-P-M-F-M2-SH-G-L-5’) (31, 73, 74).
The main viral glycoproteins at the surface of the paramyxoviruses are the attachment
protein (H, HN, or G) and the fusion protein (F) (Fig. 2) (24). The nomenclature of the attachment
proteins varies due to differences in receptor binding and neuraminidase activity. The attachment
proteins of rubulaviruses, respiroviruses, and avulaviruses have both hemagglutinin, which binds
sialic acid, and neuraminidase, sialic acid cleaving, functions and are called HN proteins. The
attachment proteins of morbilliviruses lack neuraminidase activity but can bind sialic acid, and are
called H. Pneumovirinae and Henipaviruses do not bind sialic acid, and their attachment proteins
are referred to as G, for glycoprotein. Thus, the attachment of HMPV is referred to as G (Fig. 2).
The attachment and fusion proteins mediate viral entry by coordinated activity in most
paramyxoviruses and are discussed in more detail in subsequent sections (75). In addition to the
fusion and attachment glycoproteins on the viral surface, three of the seven genera of
paramyxoviruses, including members of rubulaviruses, pneumoviruses, and the unclassified J
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virus, also express a third viral surface glycoprotein, the small hydrophobic protein (SH). Unlike
the fusion and attachment proteins, the SH protein is much less conserved across the family. Some
SH proteins are type I proteins, which contain a single transmembrane region (69), and some, like
that of PIV5 and the pneumovirinae, are type II, with multiple transmembrane domains (76). The
exact role of SH proteins in the paramyxovirus life cycle is not well understood, as most mutant
viruses lacking of this protein replicate efficiently in vitro (76-79). However, the deletion of the SH
proteins of RSV and avian metapneumovirus (AMPV) reduced replication and pathogenicity in
animal models (80-82). Furthermore, recombinant HMPV lacking the SH gene was found to
replicate in both hamster (76) and nonhuman primate models less efficiently in the lower
respiratory tract than wild-type HMPV (83). These findings suggest SH may play a role in immune
modulation in vivo, and indeed, studies with RSV (84), PIV5 (85, 86),and mumps (87) suggest that
SH antagonizes the induction of apoptosis and, like HMPV (88), may also block the activity of NFκB (89). Furthermore, all HMPV isolates to date have the SH gene, indicating its presence is
required for fitness (90). Additionally, several functions of HMPV SH have been identified
recently. Like the SH of RSV (91), the HMPV SH protein exhibits viroporin activity, serving as
channel to allow small molecules to pass across the membrane (92). Furthermore, HMPV SH can
regulate the cell-to-cell fusion activity of F (92). Additionally, HMPV SH, in addition to HMPV G,
can inhibit macropinocytosis of HMPV in dendritic cells, further supporting that the SH protein
contributes to immune evasion (93).
Paramyxovirus attachment and receptor engagement
All paramyxovirus attachment proteins characterized to date are homotetrameric type II
integral membrane proteins (24). They are made up of a membrane-proximal stalk and a large cterminal globular head domain anchored by a single-pass N-terminal transmembrane domain
(24). From the solved crystal structures of the globular head domains of several paramyxovirus
attachment proteins, it has been shown the attachment protein globular head is composed of
four six-blade β-propeller fold monomers arranged in a four-fold symmetry (94-100). The stalk
domain of the paramyxovirus attachment protein is like a helical coiled-coil that generally
interacts with the fusion protein (101-105). For most HN attachment proteins, the sialic acid
binding site is located at the top of the globular head (96), although some HN proteins, NDV (106,
107) and PIV3 (108-110), have a second binding site to sialic acid that is important for fusion
promotion.
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Most paramyxoviruses engage the cellular receptors for binding by the attachment
protein. As previously described, rubulaviruses, respiroviruses, and avulaviruses have HN
attachment proteins, and bind sialic acid with various degrees of affinity (111). The H proteins of
morbilliviruses generally bind sialic acid, and use additional cellular proteins, such as nectin-4
(112, 113) , CD46 (88), and CD150/SLAM (88) in the case of MeV, as receptors for attachment.
The G proteins of HeV and NiV bind to cellular Ephrin B2/B3 (114-116), and the G proteins of
pneumovirinae have been reported to bind heparan sulfate proteoglycans (HSPGs) (117, 118).
However, it has been shown that the HMPV fusion protein is necessary and sufficient for binding
to HSPGs (79), and that αVβ1 integrin plays an important role in promoting HMPV infection (79,
119, 120). Additionally, it has been reported that the RSV fusion protein mediates attachment to
the cell surface via nucleolin (121). Nevertheless, HMPV G can inhibit macropinocytosis of HMPV
in dendritic cells and reduce activation of CD+ helper T cells, suggesting HMPV G can regulate
particle uptake and contribute to immune evasion (93). RSV also produces a soluble form of the
G protein that plays a role in immune modulation (122). These findings suggest that, unlike
members of the paramyxoviridae subfamily, receptor binding activity for members of the
pneumovirinae subfamily can occur through the F protein and receptor interactions with the G
protein are not essential.
In addition to mediating the initial attachment of the virus to a cell, the attachment
proteins of most paramyxoviruses also have fusion promoting activity. Interaction of the
attachment protein of most paramyxoviruses with its receptor results in triggering of the fusion
protein to undergo a series of conformational changes that drives fusion of the viral envelope and
a lipid membrane of the target cell. The co-expression of the homotypic attachment and fusion
proteins is required for membrane fusion and viral spread to occur of most paramyxoviruses (101,
123-131). However, studies have shown that both RSV and HMPV are infectious in the absence of
the G protein (74, 76, 77, 132, 133). Furthermore, cell-to-cell fusion promoted by the F protein
(Fig. 3) of HMPV CAN97-83 (A2) occurs without co-expression of HMPV G (133-136). These
findings suggest HMPV G does not contribute to membrane fusion as in the trigger of the fusion
protein that is typical of attachment proteins found in paramyxoviruses.
Cellular factors required for HMPV binding
Unlike most paramyxoviruses, the binding of HMPV to target cell is mediated by the fusion
protein. Our group showed that HMPV requires the glycosaminoglycan heparan sulfate for
6

binding and infectivity, as cells deficient in heparan sulfate synthesis or treated with heparinases
were not able to bind HMPV (79). Heparan sulfate is ubiquitously expressed on the cell surface
and extracellular matrix of almost all cell types as heparan sulfate proteoglycans (HSPGs) (137,
138). Proteoglycans belong to a large class of diverse surface glycoproteins that mediate
numerous cell functions, including signaling, growth and adhesion (139-143). Heparan sulfate is
one of four glycosaminoglycans found on the surface of mammalian proteins. The biosynthesis of
glycosaminoglycans, their distinct structural feature, and different types of heparan sulfate
proteoglycans are described in detail in other sections.
Additionally, integrin αVβ1 has been identified as a binding factor and required for
efficient infection Integrins are a large family of cell adhesion proteins that are expressed in all
cell types and have critical roles in the regulation of cell-to-cell, cell-to-matrix adhesion (144),
growth, differentiation, attachment, migration, thrombus formation, and apoptosis (reviewed in
(145, 146)). Integrins are transmembrane heterodimers, composed of at least 18 different α and
10 different β subunits. Integrins serve an important role by conveying signals from the outside
to the inside of cells and vice versa, through interactions between the cytoplasmic domains of the
α and β integrin subunits with a variety of intracellular proteins (147-149). Additionally, some
integrins are known to be promiscuous and bind a variety of ligands (150), and other have specific
domains for binding many different proteins, including HSPGs (151), and proteins expressing the
amino acid sequence arginine-glycine-asparagine (RGD) (152, 153). It has reported that the HMPV
fusion protein binds through an RGD motif (119, 120). Importantly, it has been shown that
integrins such as α5β1, can play an important role in the regulation of cell signaling through
receptor-mediated endocytosis and the recycling of many surface proteins (154). Integrins are
receptors for some picornaviruses, papillomaviruses, adenoviruses, and hantaviruses (148, 155,
156). Integrin αVβ1 has been identified as a binding factor and required for efficient infection of
HMPV (79, 119, 120).
Glycosaminoglycans biosynthesis and distinct structural features
Cell surface proteoglycans consist of a diverse family of core proteins heavily modified by
sugars called glycosaminoglycans (GAGs). GAGs are divided into four major forms based on the
specific sugars that make up the repeating disaccharide units of the polysaccharide chains:
heparan sulfate, chondroitin sulfate, dermatan sulfate and keratan sulfate (Fig. 4). The steps of
biosynthesis are similar for the different forms of GAGs, although they are distinct from one
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another by the specific sugar moieties found in the repeating disaccharide units. The GAG addition
to transmembrane proteins occurs in the Golgi either by O-linked glycosylation at
serine/threonine residues or N-linked glycosylation at asparagine residues. A three or four-sugar
linkage, referred to as a oligosaccharide bridge, is created between the core protein and the
terminal glycosaminoglycan, a linear polysaccharide consisting of repeating disaccharide units, an
amine sugar and an uronic acid, with the exception of keratan. The amino sugars in the repeating
disaccharide units include N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, and in the case of
keratan, N-acetyl-D-lactosamine (Fig. 4). Typically only one type of amino sugar is found in a GAG
polysaccharide chain, but several types of GAGs may modify a single proteoglycan. The hydroxyl
groups of the amino sugars can further be modified by O-sulfation. Uronic acids are a form of
oxidized sugars, where the terminal primary alcohol is enzymatically oxidized to a carboxylic acid;
the two forms found in GAGs are glucuronic acid and iduronic acid. These epimers may both be
found in a single GAG chain.
To synthesize both the oligosaccharide bridge and GAG polysaccharide chain, specific
glycosyltransferases found in the Golgi add respective uridine diphosphate (UDP) activated sugars
initially to the protein core at one of the previously mentioned residues (Ser/Thr or Asn) and then
subsequently to the growing polysaccharide chain. After the GAG backbone is formed, the chain
can be modified by sulfation and/or epimerization of uronic acids, catalyzed by sulfotransferases
and

epimerases

respectively.

The

sulfotransferases

utilize

3’-phosphoadenosine-

5’phosphosulfate, an activated sulfate, for the addition of sulfate groups. Because of this
modification, GAGs are often highly negatively charged.
Heparan sulfate (HS) is ubiquitously expressed in most mammalian tissues. HS chains are
linked to the core protein by a tetrasaccharide bridge via O-glycosylation of a serine residue. The
first step involves the addition a xylose to the serine, followed by two galactose molecules, and
glucuronic acid. The subsequent addition of N-acetylglucosamine commits this biosynthesis
pathway to make HS; the alternative addition of N-acetylgalactosamine would result in
chondroitin sulfate synthesis (Fig. 4). Evidence has shown that the specific glucosyltransferase
that adds N-acetylglucosamine in this fate-determining step recognizes acidic residues around the
serine being modified. Interestingly, HS can be modified by sulfation like other GAGs, but HS is
uniquely found to be sulfated in clusters, as opposed to uniformly throughout the chain like in CS
and DS. Greater than 80% of HS glucosamine is N-sulfated, and even a greater percent is Osulfated (157). HS modification allows for diverse products, but analysis of HS types have found
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the HS produced is more specific to cell type rather than core proteins; therefore, different
proteoglycans produced by a single cell type express HS with a similar pattern of chain
modification, potentially contributing to tissue tropism of the viruses that bind HS. Heparan
sulfate has been identified as a binding factor for numerous viruses, including retroviruses,
herpesviruses, filoviruses, paramyxoviruses, human papilloma virus, hepatitis C virus, Dengue
virus, and baculoviruses (79, 117, 142, 158-177).
Chondroitin sulfate (CS) is primarily expressed in the central nervous system (178-181).
CS shares the first four steps of biosynthesis with HS; however, committed step to CS synthesis
involves the addition of N-acetylgalactosamine instead of N-acetylglucosamine (Fig. 4). To date,
CS has been implicated as a binding receptor for only two viruses, for porcine circovirus 2 (167)
and herpes simplex virus (182), although it has reported antiviral activity against Japanese
encephalitis (183) virus and Dengue virus (184) in vitro. Dermatan sulfate (DS) is primarily
expressed in skin tissue and is released into the extracellular matrix during wound repair (185,
186). DS has been previously been characterized as a type of CS (sometimes referred to CS type
II), although this organization has been recently questioned. Like CS, the amino sugar in the
disaccharide repeat is also N-acetylgalactosamine. However, DS contains almost exclusively
iduronic acid as the second sugar, whereas most CS contain primarily glucuronic acid (Fig. 4).
Otherwise, the synthesis of DS is similar to that that of HS and CS. Unlike other GAGs, keratan
sulfate (KS) consists of a sulfated poly-N-acetyllactosamine chain; instead of alternating amino
sugar and uronic acid, the two repeating units are N-acetlyglucosamine and galactose (Fig. 4). KS
modification on proteins is found in distinct tissues, including cartilage and the cornea of the eye
(187). The residue of KS attachment also can vary. Type I KS is linked to the protein by Nglycosylation at an asparagine residue through a three-sugar oligosaccharide bridge (Fig. 4); type
II KS is linked to the protein by O-glycosylation at a serine or threonine residue directly through
N-acetylgalactosamine (not shown). To date, neither DS nor KS have been associated with
function as a viral receptor.
Heparan sulfate proteoglycans (HSPGs) implicated in vial entry
Heparan sulfate proteoglycans (HSPGs) encompass a diverse class of proteins defined by
the substitution with HS polysaccharide chains. Because HS has been identified as the most
common type of GAG associated with attachment function for viruses, HSPGs have been
investigated in their role in attachment for numerous viruses. Indeed, the identification of HS as
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a required binding factor for HMPV infection suggests HSPGs may serve as at attachment factor
for infection. HSPGs are found both as secreted proteins in the extracellular matrix, as well as
membrane associated proteins at the cell surface of all tissues. The membrane bound HSPGs,
which could serve as a potential receptor, include two main families of cell surface proteins,
syndecans and glypicans, as well other proteoglycans including neuropilin and betaglycan.
Syndecans and glypicans regulate a wide spectrum of biological activities, including cell
proliferation, morphogenesis, wound repair, and host defense by binding proteins in the
extracellular environment as well as other plasma membrane proteins via heparan sulfate chains.
The syndecans comprise a family of four distinct genes encoding integral membrane
proteins (SDC 1-4) expressed in cell and tissue specific manner. Structurally, syndecans are similar
in the organization of protein domains: the protein is anchored by a single transmembrane
domain, with a large extracellular domain and shorter cytoplasmic tail, which consists of two
conserved regions surrounding a variable domain (188). SDC-1 is the predominant HSPG in
mammary epithelia and has been identified as an attachment factor for herpes simplex virus type
1 (158, 164) and human papilloma virus (171, 175, 189). SDC-2 is primarily expressed on
fibroblasts and cells of the vasculature (190-192). Dengue virus (168) and herpes simplex virus
type I (158) have been shown to use SDC-2 for attachment. SDC-3 is primarily expressed in the
nervous system, the adrenal gland, and the spleen (193). Finally, SDC-4 is expressed in focal
adhesions of adherent cells. Both SDC-1 and SDC-4 have been identified as mediators of HCV
attachment (165, 172). SDC-2 (194), SDC-3 (161), and SDC-4 (160) have been implicated in HIV-1
entry (reviewed in (195)). Syndecans have been identified as receptors or coreceptors for several
HS-binding viruses, possibly in part due to the fact that HS chains are attached to the ectodomains
distal to the plasma membrane on syndecan proteins, making them available for interaction.
Chondroitin sulfate chains are also found on SDC-1 and SDC-4, although closer to the plasma
membrane on the ectodomain that the HS chains.
The glypicans are a family of at least six proteins (GPC1-6) that are linked to the cell
membrane via a glycosylphosphatidylinositol (GPI) anchor (196-199). The size of the core protein
of glypicans is similar (60–70 kDa), with moderate homology among most glypicans (200). The
position of 14 cysteine residues that form disulfide bonds in the folded protein is conserved,
suggesting that the three-dimensional structure of glypicans is very similar (200). Heparan sulfate
is the only GAG that has been found on glypicans, and heparan sulfate chain ttachment sites are
restricted to the last 50 amino acids in the C-terminus, placing the chains close to the cell
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membrane (200). Glypicans are involved in mediating signaling during development,
morphogenesis, and growth. GPC3 is mutated in patients with an overgrowth syndrome, SimpsonGolabi-Behmel syndrome (SGBS) (201). Glypican expression is also cell and tissue specific, and
most glypicans are expressed predominantly in the central nervous system. However, GPC-1 is
widely expressed in other tissues including the epidermis and hair follicles (202, 203). Because
glypicans are attached to the outer membrane leaflet via a lipid anchor, they can be removed
from the cell surface using a phospholipase, specifically phospholipase C. Unlike syndecans,
glypicans have not been identified to function as receptors for viral entry until very recently. Using
a targeted RNA interference entry screen, GPC-5 was identified as a common host cell entry factor
for hepatitis B and delta viruses (204). Whether HMPV recognizes a specific HSPG for binding
remains to be determined.
Membrane fusion promoted by paramyxovirus fusion proteins
The merger of two membranes is a thermodynamically favored process, but has a high
kinetic barrier; thus, enveloped viruses utilize fusion proteins to mediate this process. All
paramyxoviruses discovered to date express a homotrimeric type I fusion protein, which are also
found in influenza, Ebola and HIV. Paramyxovirus F proteins have distinct domains that consist of
a hydrophobic fusion peptide (FP), two heptad repeat regions (HRA and HRB), a single-pass
transmembrane domain (TM), and a C-terminal cytoplasmic tail (Fig. 3A) (205). Paramyxovirus
fusion proteins are synthesized as a biologically inactive F0 precursor form which must then be
cleaved into the fusogenically active F1+F2 metastable prefusion form (Fig. 3A). Most
paramyxovirus fusion proteins are cleaved by intracellular proteases, including furin (206-208) or
cathepsin L (209-211), but for the HMPV fusion protein (F), this can be achieved by the addition
of exogenous trypsin (134). During endogenous infection in vivo, it is thought that secreted host
proteases cleave HMPV F. Upon triggering, the paramyxovirus fusion protein undergoes extensive
and essentially irreversible conformational changes (Fig. 3B) that result in the repositioning of the
heptad repeat regions to form a stable six-helix bundle (6-HB), with the released energy proposed
to drive the fusion process (75, 212). Premature activation can result in inactivation of the
attachment and fusion machinery, resulting in a defective particle no longer able to infect cells
(213). Paramyxovirus fusion proteins can promote cell-to-cell fusion when expressed at the
plasma membrane by transfection or infection, resulting in the formation of giant, multinucleated
cells called syncytia (24, 214, 215). For HMPV, studies of mutant viruses and recombinant proteins
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showed that the F protein is the major protective antigen (216-218), and the pneumovirinae
fusion protein is a common target for vaccine and antiviral development (219).
The paramyxovirus fusion proteins are minimally conserved at the amino acid level,
however structural and biochemical analysis suggest a similar structure among paramyxovirus
fusion proteins (Fig. 3B). Obtaining the prefusion conformation of the soluble globular head
domain has been challenging as most paramyxovirus fusion proteins are not stable in this form
without the transmembrane domain, thus different strategies, including the addition of a
trimerization domain (220-222), have been employed. A crystal structure of the prefusion form
of PIV5 F (222) and a partial structure of the prefusion form of HMPV F with a bound antibody
(221) have been solved. In the metastable, prefusion conformation, PIV5 F consists of a large
globular head domain and a three-helix, coiled-coil stalk domain composed of three HRB domains
proximal to the membrane (222). The HRA domain is located at the top of the globular head, and
the hydrophobic fusion peptide is buried between subunits of the trimer, leaving the cleavage site
exposed (222). Additionally, the postfusion fusion protein structures of three paramyxoviruses,
PIV3 F (223), NDV F (224), and RSV F (225), have been solved, and the formation of the 6-HB is
conserved in the solved postfusion conformation structures. Thus, it is hypothesized that
refolding of the fusion protein to form the 6-HB results in formation of the fusion pore to release
the nucleocapsid into the cytoplasm. However, it is likely multiple fusion trimers are required to
accomplish this, as cells expressing PIV5 HN and very low amounts of PIV5 F were unable to
promote membrane fusion (226).
The protein refolding that takes place to change from the prefusion to the postfusion
conformation is essentially irreversible. Therefore, the paramyxovirus fusion protein needs to be
triggered at the right time and place. For most paramyxoviruses, it is thought that interaction of
the attachment protein with cell surface receptors, and with the fusion protein, is required for
triggering (24, 227), and studies have shown that the attachment protein and the fusion protein
interact for a number of paramyxoviruses and that these specific interactions are required for
triggering (123-125, 127-129, 228-230). The interaction occurs between the globular head region
of the fusion protein (126) and different domains of the attachment protein, including the
globular head domain (229, 231, 232), the stalk domain (103-105, 130, 228, 233), and the TM
domain (234, 235). It is hypothesized that the attachment protein undergoes a conformational
change upon receptor binding, which results in the interaction with the fusion protein that
triggers fusion (95, 99, 106, 228). The fusion proteins of PIV5 and Sendai virus can promote fusion
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without the attachment protein, however the expression of the attachment protein dramatically
enhances the fusion activity (226, 236). Furthermore, the fusion proteins of paramyxoviridae can
be triggered by raising the temperature without the presence of the attachment protein (237,
238). The fusion proteins of RSV and HMPV can promote cell-to-cell fusion without the
attachment protein (134, 136, 239-242). HMPV F from CAN97-83 (A2) promotes fusion without
the G protein, with brief exposure to low pH (134, 136, 243), and co-expression of HMPV G with
this F protein does not enhance its fusion activity (134). Furthermore, recombinant RSV and HMPV
without the attachment protein are still infectious in vitro and in vivo (76, 79, 93, 134, 240, 244).
Thus, while most paramyxovirurses require the attachment protein to trigger the fusion protein,
viruses in the pneumovirinae subfamily may utilize a different mechanism.
HMPV Fusion protein
HMPV F is a homotrimeric surface glycoprotein synthesized as a 539 residue precursor
that undergoes proteolytic cleavage at the arginine at position 102 to the activated form, which
is linked by a disulfide bridge (Fig. 3A) (245). The majority of paramyxovirus F proteins are cleaved
by intracellular proteases prior to being packaged into newly formed virions (208, 210); however,
HMPV requires exogenous trypsin to be grown efficiently in cell culture, suggesting HMPV F may
be cleaved after viral budding in vivo by an extracellular protease such as TMPRSS2 (31, 246, 247).
The F protein, in the activated, or cleaved, form sits in the viral membrane as a homotrimer in a
metastable conformation until an environmental trigger causes a large conformational change in
protein structure (Fig. 3B) (221). Similarly to other paramyxovirus fusion proteins, it is predicted
that the globular head and stalk of the prefusion conformation of HMPV F refold to extend the
hydrophobic fusion peptide into the target membrane in the intermediate form. In the final postfusion confirmation the protein folds back on itself resulting in the formation of a 6-HB, which
promotes fusion between the two membranes (Fig. 3C) (205). The final protein conformation is
the lowest energy state, making this process essentially irreversible. Therefore, the initial
environmental trigger is a critical step that must be temporally and spatially coordinated for fusion
to take place (248-250).
The role of acidic pH in HMPV F triggering
The requirement for acidic pH to trigger fusion protein activity has been well described
for the fusion proteins of influenza and the rhabdovirus vesicular stomatitis virus (VSV) (251-254).
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For fusion proteins that can be triggered to fuse by low pH, it is thought that electrostatic repulsive
forces that arise between residues, often involving histidines that become protonated at low pH
and nearby basic residues contribute to the destabilization of the prefusion conformation of the
fusion protein, which then leads to refolding to the postfusion conformation (255-257). During
entry, influenza A (258-260) and VSV (261-269) require acidification of the endosome to escape
into the cytoplasm and establish infection.
The majority of paramyxovirus fusion proteins promote cell-to-cell fusion when they are
co-expressed with their respective attachment proteins, without exposure to acidic pH (24, 270272). However, HMPV F proteins can promote membrane fusion without G, and the F proteins
from some strains of HMPV can be triggered to fuse by brief exposure to low pH (134, 136, 241243). In the HMPV F protein, a conserved histidine residue at position 435 is thought to serve as
a pH sensor, and its protonation at pH values below the pKa (approximately 6.04) contribute to
triggering F (136, 242, 243). H435 is in close proximity to 3 conserved basic residues, K295, R396,
and K438, based on a homology model of the prefusion conformation, and is therefore proposed
to lead to electrostatic repulsion that results in triggering of F and fusion (136, 243). An initial
analysis of HMPV F proteins from a single prototype strain from each clade suggested low pH
triggered fusion is rare among HMPV strains (241, 242). Specifically, glycine 294 was identified as
a requirement for low pH triggered fusion, and this residue is not commonly found in HMPV F
proteins and had not been previously identified in a Clade B HMPV (241). Furthermore, additional
analysis identified residues at positions 296, 396, and 404 as the main determinants of fusion
activity among HMPV F proteins (242). HMPV F proteins that were triggered to promote cell-tocell fusion at both pH 5 and pH 7, and thus characterized as pH independent, became low pH
dependent for fusion after mutagenesis at these positions (242). These findings suggest acidic pH
is not a general factor in HMPV F trigger, however few HMPV F proteins have been studied in each
clade. Furthermore, it has only been shown that fusion activity of HMPV F is not enhanced by the
co-expression of the attachment protein G for CAN97-83 (A2) F (134). Whether acidic pH has
biological significance in the context of endocytic entry for all HMPV strains is not clear.
Mechanisms of viral entry
The fusion proteins of most paramyxoviruses promote fusion at neutral pH, and this, in
large part, has led to the hypothesis that membrane fusion occurs at the plasma membrane. Thus,
it had generally been thought paramyxovirus entry occurs by direct viral envelope fusion to the
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plasma membrane (75). However, several members of the paramyxovirus family have been
shown to utilize complex entry pathways, including different types of endocytosis and
macropinocytosis.
Endocytosis is a process to internalize substances from the extracellular environment
following activation of a surface protein, and is primarily classified as clathrin-dependent or
caveolin-dependent. Clathrin-dependent endocytosis utilizes the proteins in the AP-2 complex
and Eps15 to form a protein network around an area of the plasma membrane that invaginates
to become a vesicle (273). The GTPase dynamin is required for the final formation of the clathrincoated vesicle (273). Many viruses, including Influenza (274-277), VSV (278), and Dengue virus
(279, 280), can enter cells by clathrin-mediated endocytosis. Furthermore, the paramyxoviruses
RSV (281) and HMPV (282) have also been shown to enter cells by this route. The second major
endocytic route is caveolin-dependent endocytosis, whereby vesicles lined with the protein
caveolin-1 form from small invaginations of the plasma membrane rich in cholesterol (283, 284)
in a dynamin-dependent manner (283-285). BK virus, echovirus-1, and the paramyxovirus NDV
(286, 287) have been shown to enter cells in a caveolin-dependent manner (288-290). Both
clathrin-mediated and caveolin-mediated vesicles transport cargo into acidified endosomes (291),
where cargo is sorted and delivered to the target compartments. Many viruses utilize the acidity
of the endocytic pathway to their advantage to trigger their fusion proteins and deliver their
genomic content to the cytoplasm of the cell (261, 292-294).
Distinct from endocytic vesicle formation, macropinocytosis is a process of non-selective
internalization of large quantities of solute and membrane that has been associated with viral
entry (295, 296). Macropinocytosis involves actin-mediated membrane ruffling of the plasma
membrane, with formation of lamellipodia that fold back to fuse with the membrane to form
large, irregularly shaped vesicles called macropinosomes (reviewed in (297)). In most cell types,
macropinocytosis is a signal-dependent process that normally occurs in response to growth factor
stimulation (295), however, some specialized cell types, such as antigen-presenting cells, are
capable of constitutive macropinocytosis (298, 299). After formation, macropinosomes undergo
maturation that is associated with a reduction in surface area and acquisition of the marker of
late endosomes, Rab 7, eventually fusing with lysosomes (300). Macropinocytosis has been
implicated as the entry route for some viruses, including vaccinia virus (301), adenovirus type 3
(302), filamentous influenza (303), RSV (304), and HMPV (93), often in a cell type-dependent
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manner. Whether macropinocytosis is an entry route utilized by HMPV in non-antigen presenting
cells remains to be determined.
Evidence for HMPV endocytosis
Although not all strains of HMPV are associated with low pH promoted fusion proteins,
HMPV likely enters cells of the airway epithelium by clathrin-mediated endocytosis (282). A recent
study has shown that HMPV viral envelope fusion occurs in endosomal compartments of human
bronchial epithelial cells (282), and HMPV infection was inhibited by chlorpromazine treatment,
an inhibitor of clathrin-mediated endocytosis (136). Additionally, HMPV entry requires the GTPase
dynamin, as the inhibitor dynasore inhibited HMPV infection (136, 282). Furthermore,
lysosomotropic agents that disrupt the acidification of endosomes, such as bafilomycin A,
concanamycin A, inhibited HMPV infection to varying degrees (136, 242, 282). However, the
extent of inhibition of HMPV infection by these agents was strain dependent, and may be
associated with the requirement for acidic pH for fusion (136, 242, 282). Therefore, it likely that
most, if not all, HMPV strains enter airway epithelium cells by clathrin-mediated endocytosis, and
the fusion events may take place in various stages of endosomal maturation depending on acidic
pH requirements of each strain.
In vivo viral respiratory lung infection and challenges of in vitro modeling
The human respiratory tract is a complex histological environment in the different
anatomical regions through which air, and any potential viral pathogens, flow: from the nasal
epithelium of the nose, to the pharynx, to the bronchi and lastly the terminal alveoli where gas
exchange occurs. The respiratory epithelium is primarily lined with pseudostratified ciliated
columnar epithelium with mucus-producing goblet cells on a lamina propria. The respiratory tract
is involved in the critical function of gas exchanges, delivering oxygen to alveoli and removing
carbon dioxide waste. Additionally, the respiratory epithelium serves an important immune
function: beating cilia help to clear any potential pathogens trapped in mucus that has
antimicrobial proteins.
Because of this complexity, one of the biggest challenges of studying human respiratory
viruses is the shortage of physiologically relevant models without the use of animals. Most in vitro
studies investigating paramyxoviruses to date have been done in monolayer cell cultures derived
from immortalized animal and human cell lines. However, technical advances in manipulating cells
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to reverse cellular differentiation in order to derive tissue specific stem cells has led to the
development of the airway epithelium three-dimensional cultures. Polarized epithelium with
pseudostratified, mucociliary epithelium, as well as apical and basolateral surfaces, allow us to
investigate directional responses to pathogen exposure in vitro. The airway tissue system
represents a model of intact normal human airway epithelial cells, and has been promoted as a
valid animal-alternative model to study respiratory pathogens and testing potential therapeutic
agents (305). Human airway epithelium (HAE) has been utilized to study respiratory pathogens
haemophilus influenza, streptococcus pneumonia, influenza virus A, and HRSV (306-308). HMPV
infection at the apical surface of HAE tissues has been reported previously (El Najjar, submitted)
although features of binding and entry have not be evaluated in this model. Heparan sulfate has
been identified as a required cellular factor for HMPV binding; however, several reports have
concluded that HSPGs are not localized on the ciliated apical side of fully differentiated bronchial
epithelial cells cultured at the air-liquid interface or tracheal tissue sections (142, 309-311). HAE
presents an opportunity to apply what has been learned about HMPV since its discovery in a
physiologically relevant system. This culture system allows us to ask in vivo questions regarding
cellular responses to viral infection and conveniently answer them utilizing an in vitro system.
Dissertation Overview
Human metapneumovirus (HMPV) is an enveloped RNA virus that causes severe
respiratory disease in infants, the elderly, and immunocompromised patients worldwide. Despite
its prevalence and importance to human health, no therapies are available against this pathogen.
Key features of early events in HMPV infection have been identified. However, many important
aspects of binding and fusion events remain unknown. This body of work characterized critical
aspects HMPV F protein triggering by low pH, which has biological relevance for endocytic entry.
It was previously demonstrated low pH can promote fusion activity of the F protein from some
strains of HMPV, but analysis of a limited number of other strains suggested this is a rare
characteristic and requires specific residues. Analysis of F proteins from phylogenetically diverse
HMPV strains showed low pH triggered fusion, challenging previously thought requirements, and
led to the identification of a critical residue that enhances low pH promoted fusion. These results
support our hypothesis that electrostatic interactions play a key role in HMPV F triggering by low
pH and further elucidate the complexity of viral fusion proteins.
17

Previous work showed HMPV F mediates attachment to HSPGs. We characterized the key
features of the binding interaction between HMPV and HSPGs using heparan sulfate mimetics,
identifying an important sulfate modification, and demonstrate that these interactions occur at
the apical surface of polarize airways tissues. These results significantly advance our
understanding of HMPV infection in the human airway and identify an antiviral strategy.
Furthermore, in our analysis of HMPV F mediated binding to HSPGs, we identified regulatory roles
of HMPV glycoproteins G and SH that affect binding mediated by F and a potential novel function
for HMPV G in actin recruitment. These results contribute to our understanding of the HMPV G
and SH, which often do not share the same functional roles of analogous proteins found in viruses
of the same family.
While a majority of the work presented here examined mechanisms of early events of
entry, we also characterized HMPV infection in a clinical scenario using cystic fibrosis bronchial
epithelial (CFBE) cells. Compared to paramyxoviruses RSV and PIV5, CFBE were specifically more
permissive to HMPV infection, which correlates to the limited number of epidemiological studies
of virus infection in cystic fibrosis patients. Our results identified a potential specific susceptibility
to HMPV infection, which has not been previously reported. Therefore, the work presented here
contributes to our understanding of HMPV infection over a broad breadth, from mechanisms of
early events of entry to a clinical model of chronic respiratory disease.
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Figure 1. Paramyxovirus family.
Figure is adapted from (312).
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Figure 2. HMPV particle structure.
The three glycoproteins found on the surface of HMPV include the attachment protein (G), the
homotrimeric fusion protein (F), and the small hydrophobic (SH) protein. The viral envelope (red)
is derived from host cell plasma membrane in part due to the assembly of the matrix protein (blue
ovals), which closely associated with the inner leaflet of the viral envelope. The nucleocapsid
surrounds the negative sense, single stranded RNA genome and contributes to the replication
machinery required during infection.
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Figure 3. HMPV F protein: processing and predicted structures
(A) The HMPV F protein includes: a hydrophobic fusion peptide (blue), heptad repeat A (HRA)
(orange) and heptad repeat B (HRB)(green) domains, the transmembrane (TM) domain (red), and
the cytoplasmic tail (brown). The inactive precursor F0 undergoes proteolytic cleavage, resulting
in protein fragments F1 + F2 linked by a disulfide bridge. (B) Structures of the uncleaved form of
PIV5 F in its prefusion conformation (222) and (C) the hPIV3 F in its postfusion conformation (223),
adapted from (312).
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Figure 4. Glycosaminoglycans
Representative structures of glycosaminoglycans (GAGs) heparan sulfate, chondroitin sulfate,
dermatan sulfate, and keratin sulfate type I. All four types of GAGs can be further modified by Nsulfation and O-sulfation.
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Chapter 2: Materials and Methods
Cells and tissues
Vero cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco)
supplemented with 10% fetal bovine serum (FBS). BSR cells (provided by Karl-Klaus Conzelmann,
Max Pettenkofer Institut) were grown in DMEM supplemented with 10% fetal bovine serum and
1% penicillin and streptomycin (P/S). The medium of the BSR cells was supplemented with 0.5
mg/ml G-418 sulfate (Gibco Invitrogen, Carlsbad, CA) every third passage to select for T7
polymerase-expressing cells. A549 cells were grown in Roswell Park Memorial Institute medium
(RPMI; Lonza) supplemented with 10% FBS. BEAS-2B cells, a human bronchial epithelial cell line,
obtained from ATCC, were maintained in BEGM medium containing all the recommended
supplements (Lonza) in flasks coated with bovine collagen (Sigma), bovine fibronectin (VWR
Scientific) and bovine serum albumin (EMD Millipore). Cystic fibrosis bronchial epithelial (CFBE)
cells were kindly supplied by Carolyn Coyne from the University of Pittsburg. CFBE cells were
grown in DMEM supplemented with 10% FBS, 1 mM of non-essential amino acids (Gibco), and 1
mM of sodium pyruvate (Invitrogen). All cells were grown at 37°C under 5% CO2.
Well-differentiated (transepithelial resistance >1000 Ohm) primary normal bronchial
human airway epithelial (HAE) tissue cultures were purchased from MatTek Corp. (Ashland, MA,
USA). Cell culture inserts were placed atop two washers (MatTek) in 6-well plates with 5 mL AIR
100 growth medium (MatTek) in contact with the basal surface and incubated at an air-liquid
interface at 37°C and 5% CO2. Tissues were maintained for 5 -7 days for differentiation after arrival
by washing the apical surface with 0.9% sodium chloride and changing the media every 48 hours
prior to initiation of infection experiments.
Plasmids
HMPV virus strains were kindly provided by the designated sources: CAN97-83 (Ursula J.
Buchholz, NIAID), TN83-1211 (BEI Resources), TN94-49 and TN96-12 (John Williams, U. of
Pittsburg). RNA was isolated from viruses propagated in Vero cells as by phenol-chloroform
extraction. Briefly, 100 µL of virus solution was resuspended in 800 µL Tripure and incubated at
room temperature for 5 min. Next 200 µL chloroform was added and the sample was shaken
vigorously for 15 sec and let stand for 15 min. The sample was centrifuged for 15 min at 12,000xg
at 4°C. The top (colorless) layer containing the RNA was transferred to a new tube and 500 µL
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isopropanol added. The RNA was allowed to precipitate for 10 min at room temperature and
pelleted by centrifugation for 10 min at 12,000 x g, at 4°C. 1mL 75% ethanol was added to the
pellet. After inverting to mix, the samples were centrifuged for 5 min at 7,500 x g at 4°C. The
supernatant was discarded and the pellet air-dried overnight. The RNA was resuspended in 50µL
DEPC treated water.
The F genes were amplified from RNA using the following primers designed with EcoR1
restriction

sites

upstream

and

downstream

of

the

gene:

forward

primer

5’AAAGAATTCGCTAGCAATCAAGAACGGGACAAATAAAAATGTCTTGGAAAGTGGTGATCATTTTTTCAT
TGC and reverse primer 5’AAAAAAGAATTCTTTAATTAACTAA-CTGTGTGGTATGAAGCC. Using the
SuperscriptIII One Step RT-PCR system (Invitrogen) according to manufacturer’s protocol, the
gene was amplified using the following thermocycler settings: 1 cycle at 55°C for 30 min, 1 cycle
at 94°C for 2 min, 40 cycles of the following three steps: 94°C for 15 sec, 60°C for 2 min, 68°C for
1 min, then 1 cycle at 68°C for 5 minutes. The amplified product was held at 15°C until it was
confirmed by gel electrophoresis, and bands corresponding to F (1600bp) were excised and
purified. The inserts were digested with EcoR1 and ligated into alkaline phosphatase-treated
pCAGGs overnight at 16°C using T4 DNA Ligase (New England BioLabs). Competent E coli cells
were transformed with ligation product and plated on plates with Ampicillin. After 12-18 hr of
growth at 37°C, colonies were screened for an insert. Correct orientation of insert in pCAGGS was
determined by digestion with Pac1 (restriction site in forward primer) and Xba1 (restriction site
in pCAGGS) digestion, with proper orientation giving bands of sizes 1754 bp and 4651 bp. The
CAN97-83 434H F mutant was created using the gene in pGEM-3Zf(+) using QuikChange sitedirected mutagenesis (Stratagene) and subcloned back into pCAGGS. All F expression plasmids
were sequenced in their entirety and BioEdit was used for sequence analysis.
Antibodies
A rabbit polyclonal antibody against avian metapneumovirus (AMPV) C matrix (M) protein
supplied by Dr. Sagar Goyal (University of Minnesota) with cross reactivity to HMPV M was used
to detect HMPV M protein by Western blot (313). All other antibodies were purchased from the
following companies: β-actin (Sigma), Peroxidase AffiniPure Goat Anti-Rabbit IgG and Peroxidase
AffiniPure Goat Anti-Mouse IgG (Jackson Immuno Research). Antipeptide antibodies to HMPV F
(Genemed Synthesis, San Francisco, CA) were generated using amino acids 524 to 538 of HMPV F
(314).
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Syncytium assay
Subconfluent monolayers of Vero cells in 6-well plates were transiently transfected with
a total of 2 μg of DNA consisting of pCAGGS-HMPV F derived from CAN97-83, CAN97-83 mutant
434H, TN83-1211, TN49-49 or TN96-12, or the empty pCAGGS vector, using Lipofectamine Plus
reagents (Invitrogen) according to the manufacturer's instructions. The next morning, confluent
cell monolayers were washed with PBS (phosphate buffered saline; Invitrogen) and incubated at
37°C in Opti-MEM (Gibco) with 0.3 μg/ml TPCK (l-1-tosylamide-2-phenylethyl chloromethyl
ketone)-trypsin (Sigma) for 1 hr. Then the cells were rinsed once with PBS (pH 7.2) before PBS of
the indicated pH, buffered with 10 mM HEPES and 5 mM MES (2-(N-morpholino)ethanesulfonic
acid hemisodium salt), was added. Cells were incubated for 4 min at 37°C with PBS pH 5 or pH 7,
and then the media was replaced again with Opti-MEM with 0.3 μg/ml TPCK-trypsin. The pH pulse
was repeated three more times (2 hr apart) throughout the day. Vero cells were incubated
overnight at 37°C to allow syncytia formation to take place. Digital photographs of syncytia were
then taken with a Nikon Coolpix995 camera mounted on a Nikon TS100 inverted phase-contrast
microscope using a 5X objective. Quantification of syncytia formation is reported as a fusion index,
as previously reported (315). Briefly, the fusion index was calculated using the equation f = [ 1 – (
C / N ) ] where c is the number of cells in a field after fusion and n the number of nuclei. Six fields
were scored per condition representative of 3 independent experiments.
Reporter gene fusion assay
Vero cells in 6-cm dishes were transfected using Lipofectamine Plus reagents (Invitrogen)
with 1.5 μg pCAGGS-HMPV F derived from CAN97-83, TN83-1211, TN49-49 or TN96-12 or CAN9783 mutant 434H or empty pCAGGs control, and 1.5 μg T7 control plasmid (Promega) containing
luciferase cDNA under the control of the T7 promoter. The following day Vero cells in one 6-cm
dish were lifted with trypsin, a process which also efficiently cleaved the HMPV F protein. The
cells were resuspended in DMEM plus 10% FBS and overlaid onto two 35-mm dishes of confluent
BSR cells, which constitutively express the T7 polymerase. The combined cells were incubated at
32°C for 2 hr. The cells were then rinsed once with PBS (pH 7.2) before adding pH 5 or 7 PBS
buffered with 10 mM HEPES and 5 mM MES (morpholineethanesulfonic acid). The cells were
incubated for 4 min at 37°C under the indicated pH conditions, and then Opti-MEM with 0.3 μg/ml
TPCK-trypsin was added. The cells were again incubated at 32°C for 1 hr, and then the cells were
treated with pH 5 or 7 PBS as before. DMEM with FBS was added after this treatment, and the
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cells were incubated at 37°C for 4 hr. Finally, the cell lysates were analyzed for luciferase activity
using a luciferase assay system (Promega) according to manufacturer's protocol. Light emission
was measured using an Lmax luminometer (Molecular Devices, Sunnyvale, CA).
Surface expression of proteins, metabolic labeling, and immunoprecipitation
Vero cells were transiently transfected with 4μg pCAGGS expression vectors using
Lipofectamine Plus reagent. At 18 to 24 hr posttransfection, the cells were starved in methionineand cysteine-deficient DMEM for 30 min and then metabolically labeled with Tran35S-label (100
μCi/ml; MP Biomedicals) for 3 hr with or without the presence of 0.3 μg/ml TPCK-trypsin. The cells
were washed three times with cold pH 8 PBS and incubated with 1 mg/ml EZ-Link Sulfo-NHS-Biotin
(Pierce, Rockford, Ill.) diluted in pH 8 PBS for 15 min of rocking at 4°C and then 30 min at room
temperature. The cells were washed twice with PBS before

being lysed with

radioimmunoprecipitation assay buffer containing 100 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1%
sodium dodecyl sulfate (SDS), 1% Triton X-100, 1% deoxycholic acid, protease inhibitors (1
KalliKrein inhibitory unit of aprotinin, [Calbiochem, San Diego, Calif.] and 1 mM
phenylmethylsulfonyl fluoride [Sigma, St. Louis, Mo.]), and 25 mM iodoacetamide (Sigma). The
lysates were centrifuged at 136,500 × g for 10 min at 4°C, and the supernatants were collected.
Antipeptide sera and protein A-conjugated Sepharose beads (Amersham, Piscataway, N.J.) were
used to immunoprecipitate the F proteins as previously described (316). The beads were boiled
twice in 10% SDS for 10 min to release the proteins. Ten percent of the total protein was removed
for analysis, and the remaining 85% was incubated with immobilized streptavidin (Pierce) for 1 hr
at 4°C. Then biotin-labeled protein bound to streptavidin was pulled down and released by boiling
with loading buffer. The immunoprecipitated F proteins were analyzed via SDS-15%
polyacrylamide gel electrophoresis (SDS-PAGE) and visualized using the Typhoon imaging system.
Homology modeling
The DeepView/Swiss-PdbViewer v3.7 (www.expasy.org/spdbv/) was used to generate
homology models of the HMPV F protein in prefusion and postfusion conformations as previously
described (136, 243). The prefusion model of HMPV F was created by threading the amino acid
sequence was threaded onto the crystal structure of PIV5 F in its metastable prefusion form (222).
The postfusion homology model of HMPV F was created by threading the amino acid sequence of
HMPV into the crystal structure of Newcastle Disease Virus F in its postfusion conformation (317).
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Heparan sulfate mimicking and occluding compounds
Iota-carrageenan was purchased from Sigma (Invitrogen). Peptide dendrimer SB105-A10
([H-ASLRVRIKK]4 Lys2-Lys-β-Ala-OH) was synthesized by Lifetein with a purity of >95%. Escherichia
coli K5 polysaccharides derivatives were provided by David Lembo and Glycores 2000 (318).
Cell viability assay
Approximately 10,000 BEAS-2B or A549 cells were grown in triplicate overnight in a 96
well plate. BEAS-2B cells were either incubated with 2 µM SB105-A10 for 1 hr, 40 µg/mL iotacarrageenan for 4 hr, or 10 µM of each of the K5 derivatives for 4 hr at 37°C. A549 cells were
incubated with 2 µM SB105-A10 for 1 hr at 37°C. Control cells were incubated with OptiMEM,
which was used to dilute all of the compounds. Then 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl2H-tetrazolium bromide (MTT; Fisher Scientific) (5 mg/mL) was added and incubated for 3 hr at
37°C. The media was removed from the cells by tapping the plate and blotting excess liquid. Next,
100 µL of stop solution (90% isopropyl alcohol, 10% DMSO) was added and the plate was
incubated at room temperature for 20 minutes in the dark with rocking. Absorbance was read at
590 nm using a plate reader. Absorbance of treated cells was normalized to the untreated control.
Virus propagation and titers
Recombinant, green fluorescent protein (GFP)-expressing HMPV (rgHMPV) strain CAN9783 (genotype group A2) and the mutant viruses HMPV ΔG and HMPV ΔG/ΔSH with a codonstabilized SH gene (319) were kindly provided by Peter L. Collins and Ursula J. Buchholz (NIAID,
Bethesda, MD). The viruses were propagated in Vero cells (starting multiplicity of infection [MOI],
0.01 to 0.03) and incubated at 37°C with Opti-MEM, 200 mM l-glutamine, and 0.3 μg/ml
tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin (Sigma), replenished every day. On
the fifth day, or when cytopathic effects were observed in at least 25% of the cells, cells and
medium were collected and subjected to centrifugation at 2,500 × g for 10 min at 4°C in a Sorvall
RT7 tabletop centrifuge. The supernatant was then stored in 1× sucrose phosphate glutamate
(SPG) (218 mM sucrose, 0.0049 M l-glutamic acid, 0.0038 M KH2PO4, 0.0072 M K2HPO4), and
aliquots were flash frozen in liquid nitrogen and thawed twice prior to storage at −80°C. To
achieve more concentrated rgHMPV for HAE tissue experiments, supernatants of harvested cells
and medium were subjected to centrifugation on a 20% sucrose cushion for 3 hr at 27,000 × g at
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4°C using a SW28 swinging-bucket rotor on a Beckman Optima L90-K ultracentrifuge. Following
centrifugation, the supernatant was removed, and the pellet was resuspended in 100 μl OptiMEM per T75 flask harvested, and left at 4°C overnight. Aliquots were stored at −80°C by flash
freezing in liquid nitrogen.
Recombinant GFP-expressing parainfluenza virus 5 (rgPIV5) was kindly provided by Robert
Lamb (Howard Hughes Medical Institute, Northwestern University) (136). rgPIV5 was propagated
in MDBK cells as described previously (316) and stored in 1× SPG. Aliquots were frozen in liquid
nitrogen and thawed twice prior to storage at −80°C. Recombinant GFP-expressing respiratory
syncytial virus (rgRSV) was provided by Mark Peeples (The Ohio State University).
For GFP-expressing viruses (rgHMPV, rgPIV5, and rgRSV), viral titers were calculated by
creating serial dilutions of the viral samples in Opti-MEM. Vero cells were seeded on a 96-well
plate overnight and infected in serial dilution (10-1 to 10-12) with 50µL of virus solution in duplicate.
The number of GFP-expressing cells was counted in wells demonstrating 25-100 GFP-positive cells
the following day. Average titer was calculated based on the dilution of the virus solution in the
wells counted.
For non-GFP expressing viruses (HMPV ΔG and HMPV ΔG/ΔSH) viral particles were
estimated using serial dilutions of viral samples assessed for M protein content using Western
blot and compared to protein levels of an rgHMPV standard of known titer. Volumes of untitered
virus and the rgHMPV standard of known titer (2, 4, and 8 µL in duplicate) were resolved on 15%
SDS-PAGE, and the proteins were transferred to a PVDF membrane (Fisher) at 50 volts for 80 min.
The membrane was blocked with Odyssey Blocking Buffer (Li-Cor) at 4°C overnight and incubated
with anti-AMPV M antibody (1:500) in PCT (PBS; phosphate buffered saline (Invitrogen) with
casein and 0.2% Tween-20) for 3 hr at room temperature. The membrane was washed with t-TBS
(0.2% Tween-20 in 1X TBS (Tris buffered saline)) and incubated with Peroxidase AffiniPure Goat
Anti-Rabbit secondary antibody (1:10,000) in PCT for 1 hr at room temperature. The membrane
was washed with t-TBS and incubated with SuperSignal West Pico Chemiluminescent Substrate
(Fisher) for 10 min in the dark prior to development by ECL. Densitometry was quantified using
ImageQuantTL, and an average density units of M protein per µL of virus input was calculated for
each sample. Titer was determined by comparing to the standard of known titer.
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Cell infection assay
BEAS-2B cells were grown to low confluency (approximately 50,000 cells per well; as
recommended by ATCC) in a 24 well plate overnight. Iota-carrageenan solution was freshly
prepared in PBS at 0.7 mg/mL by incubating at 55°C with brief vortexing. Virus was pretreated
with iota-carrageenan or K5 polysaccharide derivatives diluted in OptiMEM for 30 min at 4°C with
rocking. Cells were washed two times with PBS and 200µL of virus solution was added at MOI of
1. For SB105-A10 experiments, BEAS-2B or A549 cells were washed 2 times with PBS, and
incubated with 200µL of SB105-A10 diluted in Opti-MEM at variable concentrations at 37°C for 1
hour. Cells were washed once with PBS and infected with 200 µL of virus solution in OptiMEM at
an MOI of 1. For all treatments, cells were incubated with the infection media in duplicate for 2
hours at 37°C with rocking every 30 min. After 2 hr, cells were washed twice with PBS, and
infection media was replaced. For GFP expressing virus, following an overnight incubation, cells
were resuspended, fixed in 2% formaldehyde diluted in PBS with 50 mM EDTA, and analyzed with
a BD FACS Calibur flow cytometer, for which the GFP expression of at least 10,000 cells were
determined. Data analysis was performed using FCS Express software, and data presented in
graphs represent the percentage of GFP-expressing cells as a percentage of the untreated control
as previously described (79).
HAE infection assay
HAE tissues were maintained according to the manufacturer’s recommendations for 5-7
days after arrival. Tissues were transferred to a new 6-well plate with 1 ml of Hepes buffered
saline (HBS; 150 mM NaCl, 20 mM HEPES pH 7.5, 1 mM MgCl2 and 1 mM CaCl2) and washed with
400 µL of sterile 0.9% NaCl. The apical surface was washed 3 times with 75 µg/mL
lysophosphatidyl choline (LPC; Sigma) in HBS for 10 min at room temperature (320). LPC was
removed from the apical surface, and HBS from the basal surface of the tissues, and 1mL of AIR
100 Growth Medium was added to the basal side. To measure the effects of heparan sulfate
mimics, rgHMPV or rgPIV5 at MOI of 5 (calculation was based on 0.8x106 cells per tissue according
to manufacturer) was pretreated either with 40 µg/mL iota-carrageenan, 10µM K5-N,OS (H) or
10µM K5-OS(H) (untreated control received Opti-MEM) in a total volume of 100 µL. For SB105A10, the tissues were treated with 2 µM SB105-A10 in Opti-MEM for 1 hr at 37°C prior to infection
(untreated control tissue was incubated with Opti-MEM). The infection solution (100 µL at MOI
of 5) was added to the apical surface of the tissues drop-wise, and the tissues were incubated at
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37°C for 2 hours with rocking every 30 min. After 2 hr, the infection media was aspirated, and the
apical surface washed 1X with 200µL of HBS. Fresh AIR 100 Growth Medium with 0.3 μg/ml TPCKtrypsin was added to each well and incubated at 37°C. After 48 hr, the apical surface of the tissues
was imaged for GFP expression using an Axiovert-100 (3 fields per tissue) at 5X magnification. The
number of infected cells was determined by counting GFP-expressing cells and averaged per
tissue. The results are reported as a percent infection of the untreated control.
Cell binding assay
Approximately 250,000 BEAS-2B cells were cultured overnight in a 6-well plate. rgHMPV
was pretreated with iota-carrageenan at 40 mg/mL or 1µM of the K5 polysaccharide derivatives
diluted in Opti-MEM for 30 minutes at 4°C with rocking. For SB105-A10 treatment, cells were
washed two times with PBS and incubated in a 200 µL solution of SB105-A10 diluted in Opti-MEM
at 37°C for 1 hour. For all treatments, cells were washed twice with cold PBS and infected with
500µL of virus solution at an MOI of 1 for 2 hr at 4°C with rocking to prevent internalization. Cells
were washed with PBS 3 times, lysed using 45 μl of RIPA buffer with 0.15 M NaCl with a complete
protease inhibitor cocktail tablet (Fisher), and frozen at -80°C. Cells were thawed and scraped on
ice, and lysates were cleared by centrifugation for 10 min at 55,000 rpm at 4°C (Sorvall Discovery
M120). Western blot analysis for M to quantify bound HMPV was carried out as described above.
Statistical Analysis
All data are presented as mean +/- standard deviation. A standard Student's t-test or oneway ANOVA was performed when appropriate to analyze the differences between the individual
experiments with statistical significance set as p≤0.05. Post-hoc Bonferroni’s multiple comparison
test (GraphPad Prism) was used within one-way ANOVA to identify specific differences between
groups.
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Chapter 3: HMPV fusion protein triggering: Increasing complexities by analysis of new strains
*This work was completed with the help of Andres Chang, who cloned the fusion proteins from
HMPV CAN97-83, TN94-49 and TN96-12 and designed the primers for this construct. Andres
Chang also created the homology model for the prefusion and postfusion structures of HMPV F
and identified the exposed basic residues on the surface of HMPV F that may contribute to
interaction with heparan sulfate. Viruses TN94-49 and TN96-12 were kindly provided by John
Williams (University of Pittsburg).
Introduction
Human metapneumovirus (HMPV), an enveloped, negative-sense, single-stranded RNA
virus in the Paramyxoviridae family, is a common cause of both upper and lower respiratory tract
infections (30, 31, 321). First identified in 2001 in the Netherlands, HMPV is now known to be the
cause of respiratory infections in humans since at least 1958 (31). HMPV strains have been
phylogenetically classified into two genetic lineages (A and B) with distinct sublineages (A1, A2,
B1, and B2) (32). Nearly all people are initially infected with HMPV in early childhood, and
reinfection throughout life is common (7). Respiratory disease caused by HMPV can vary in
severity, from mild cold-like symptoms to severe lower respiratory tract infection such as
pneumonia and bronchiolitis (321, 322). Infants, immunocompromised and geriatric patients are
most likely to foster severe infection (37, 38, 43-45). There is no vaccine or antiviral treatment
against HMPV.
To infect cells, enveloped viruses fuse the viral envelope with membranes of the target
cell, a process mediated by one or more surface viral glycoproteins. For HMPV, this process can
occur in endosomes (282) and is mediated by the fusion protein (F). HMPV F proteins, like all
paramyxovirus F proteins, are trimeric type I fusion proteins. To become active, paramyxovirus F
proteins undergo proteolytic cleavage of the precursor form of the protein (F0) into an active,
disulfide-linked form (F1+F2) (75, 212). For HMPV F, this can be achieved by the addition of
exogenous trypsin (134), although it is thought secreted host proteases cleave F during infection
in vivo.
The paramyxovirus F protein undergoes an essentially irreversible conformational change
during the process of membrane fusion, with the released energy proposed to drive the fusion
process. The triggering event that drives these conformational changes for the majority of
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paramyxovirus F proteins is hypothesized to occur following attachment of the virus to its
receptor, requiring the coordinated activity of an attachment protein and a fusion protein
(reviewed in (212)). However, HMPV attachment and fusion is dependent on F alone (79, 134,
136). Furthermore, HMPV F promotes cell-to-cell fusion without the putative attachment protein,
G (134, 136, 241, 242). This suggests HMPV F is triggered to fuse by environmental and host
factors in the right time and place.
There is direct evidence HMPV can enter target cells by endocytosis in epithelial and
endothelial cells. Antigen presenting cells of the immune system can take up HMPV by
micropinocytosis (93). However, HMPV particles are internalized via clathrin-mediated
endocytosis in human bronchial epithelial cells (282), which requires dynamin (136, 282).
Furthermore, viral membrane fusion has been shown to take place in endosomes (282). Our group
and others have shown HMPV infection for at least some strains can be inhibited by interfering
with acidification of endosomes, suggesting low pH can contribute to HMPV infection (136, 242,
282). Many paramyxovirus F proteins can promote fusion at neutral pH (75). However, low pH can
trigger the fusion of activity of HMPV F from some strains, including HMPV strain CAN97-83 (clade
A2) (134, 136). For fusion proteins that can be triggered to fuse by low pH, it is thought that
electrostatic repulsive forces that arise between residues, often involving histidines that become
protonated at low pH and neighboring basic residues contribute to the destabilization of the
prefusion conformation of F, which then leads to refolding to the postfusion conformation (255257). In HMPV F, a conserved histidine residue (H435) in the heptad repeat B linker domain is
thought to serve as a pH sensor and contribute to triggering F (136, 242). H435 is in close proximity
to 3 conserved basic residues, K295, R396, and K438, based on a homology model of the prefusion
conformation, and is therefore proposed to lead to electrostatic repulsion that results in
triggering of F and fusion (136, 243). Studies with recombinant HMPV with mutations in this
region confirmed its importance for virus infectivity (243).
While the trigger of CAN97-83 (A2) F by acidic pH has biological significance in the context
of endocytic entry, low pH is not required for fusion activity for F proteins for all strains of HMPV.
An initial analysis of F proteins from a single prototype strain from each clade revealed low pH
triggered fusion is rare among HMPV (241). Specifically, glycine 294 was identified as a
requirement for low pH triggered fusion, and this residue is not commonly found in HMPV F
proteins (241). Furthermore, additional analysis identified residues at positions 296, 396, and 404
as the main determinants of fusion activity among hMPV F proteins (242). These findings suggest
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acidic pH is not a general factor in HMPV F trigger, however few HMPV F proteins have been
studied in each clade.
In this study, we analyzed the different fusion activity of HMPV F proteins from three
unique strains: TN83-1211 (Clade B2), TN94-49 (Clade A2), and TN96-1211 (Clade A1). We
identified an F protein from TN83-1211 (B2) that promotes greatly enhanced fusion after low pH
pulses compared to CAN97-83 (A2) F, and determined the specific residue, H434, is a key
contributor to this hyperfusogenic phenotype, supporting the hypothesis that electrostatic
interactions in this region play a key role in HMPV F triggering. Furthermore, we characterized an
F protein from strain TN94-49 (A2) that promotes cell-to-cell fusion after low pH pulses without
residue G294, which has been previously thought to be required for low pH promoted fusion.
Lastly, we identified an F protein from TN96-12 (A1) that failed to fuse in cell-to-cell fusion assays,
suggesting additional host factors are required for triggering for this HMPV F. Taken together,
these results further elucidate the complexity of HMPV F proteins and provide insights to how
fusion is regulated in endosomal compartments to establish infection.
Results
Different fusion activity of HMPV F proteins
We previously showed that the fusion protein (F) derived from HMPV strain CAN97-83
(A2) could be triggered to promote membrane fusion by short exposure to low pH (134, 136).
However, fusion by F proteins from other strains, specifically those in the B genetic lineage, were
not low pH triggered in studies from other groups, suggesting low pH is not a requirement for
fusion for F proteins of all strains of HMPV (241, 242). However, F proteins from only a small
number of strains within each clade have been examined. We therefore characterized the fusion
activity of F proteins from several additional strains and determine how these results fit with the
current understanding of essential residues involved in low pH triggered HMPV F (136, 241, 242,
314). The F genes were cloned from the following strains of HMPV, with the respective clades
indicated in parentheses: TN83-1211 (B2), TN94-49 (A2), and TN96-1211(A1). Because the primer
design also included short intergenic upstream and downstream of F, CAN97-83 (A2) F was also
cloned using the same expression construct so that activities between the different F proteins
could be directly compared. To determine if the F proteins could be triggered to promote
membrane fusion by low pH exposure, Vero cells transiently expressing the different F constructs,
or the control expression plasmid without F, were exposed to a serious of pulses of buffer at pH
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5 or 7. The cells were visualized for cell-to-cell fusion, syncytium formation, the following day. In
addition to imaging the cells, the fusion index was calculated for each strain (315). As previously
reported, CAN97-83 (A2) F promoted cell-to-cell fusion after brief exposure to low pH pulses, as
did TN94-49 (A2) to a same degree (Fig. 5A). Interestingly, TN96-12 (A1) F failed to fuse with low
pH or neutral pH exposure, whereas TN83-1211 (B2) caused robust syncytia formation that was
more extensive than that observed with CAN97-83 (A2) F at low pH (Fig. 5A and 5B). While the
fusion index serves as a representative quantitation of syncytia formation, we used a luciferase
reporter gene assay as quantitative measure of cell-to-cell fusion by the F proteins (134). Vero
cells transfected with the F construct and a plasmid encoding the luciferase enzyme under a T7
promoter were overlaid on BSR cells, which are stably transfected to express the T7 polymerase.
Cells were treated with pH 5 or 7 buffer and cell lysates were analyzed for luciferase activity. As
observed with the syncytia assay, TN94-49 (A2) F exhibited similar fusion activity as CAN97-83
(A2) F under low pH conditions, and TN83-1211 (B2) F exhibited fusion activity nearly 500% of
CAN97-83 (A2) F (Fig. 5C). Fusion activity of TN96-12 (A1) was not observed above background
(Fig. 5C).
HMPV F protein surface expression and proteolytic processing
To verify that the varying fusion activity observed for F proteins from the different strains
were not a results of changes in surface expression, we performed surface biotinylation. The
antibody used to recognize F for immunoprecipitation is a polyclonal antibody generated using
amino acids 524 to 538 of CAN97-82 (A2) F and all 4 of the F proteins in these studies are
completely conserved in this region (Fig. 6). There was no significant difference in total (Fig. 7A)
and surface expression (Fig. 7B) of F from the different strains (Fig. 7C).
While HMPV F is synthesized as a single protein (F0), it must be cleaved into fragments F1
and F2, which are linked by disulfide bonds, to be fusogenically active. In cell assays exogenous
trypsin is added to cells to cleave F (34, 73, 90, 323). Although we found equivalent surface
expression of the different F constructs, it was possible they are not recognized by trypsin to the
same degree. To determine if the different F proteins were not being cleaved by trypsin with the
same efficiency, we examined the ratio of surface expression of cleaved F (F1) compared to total
F, cleaved (F1) and uncleaved F (F0). Incubation of the cells with trypsin during metabolic labeling
revealed the four F constructs are processed to similar efficiency (Fig. 7D, which suggests
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differences in trypsin cleavage at the plasma membrane do not account in the variable fusion
activity.
Sequence differences in HMPV F proteins and role of H434
Because the surface expression and cleavage efficiency of the F proteins did not differ
among the F proteins from different strains, we examined the nucleotide and amino acid
sequences to identify potential residues that could explain the different fusion activities. HMPV F
is highly conserved, thus sequence analysis revealed only a small number of differences at the
amino acid level (Fig. 6). While there were 37 nucleotide differences between CAN97-83 (A2) and
TN94-49 (A2), these only resulted in 6 amino acid differences. One key difference was noted at
residue 294, as TN94-49 (A2) did not have a glycine but rather lysine at this position (Fig. 8A).
Therefore, TN94-49 (A2) F does not require G294 for low pH triggering, in contrast to the previous
suggestion that G294 is required for clade A F proteins for low pH triggering (241, 242).
Comparison of CAN97-83 (A2) and TN96-12 (A1) revealed 86 nucleotide differences and 9
differences at the amino acid level, though the role of each of these residues in fusion is still
unclear. TN96-12 (A1) F lacks G294, previously hypothesized to be critical for low pH triggering,
but this residue is also absent in TN94-49 (A2) F, which is low pH triggered. Despite a greater than
400% increase in fusion activity promoted by low pH, TN83-1211 (B2) F differs from CAN97-83 by
only 3 nucleotides, which result in differences at two amino acid positions, R175S and Q434H (Fig.
8B). Histidine 434 specifically was noted because it is immediately adjacent to conserved histidine
435, which is required for fusion activity of CAN97-83 (A2) F and is thought to play a critical role
in electrostatic repulsion with neighboring cationic residues after protonation at low pH (134, 136,
243).
Fusion activity of CAN97-83 F Q434H mutant
Based on these findings, we hypothesized the additional histidine in this region of F results
in hyperfusogenic activity at low pH. To confirm that this residue is essential for the observed
hyperfusogenic phenotype, a point mutation was introduced to CAN97-83 (A2) F at this position
by site directed mutagenesis and verified by sequencing. To characterize the fusion activity of the
CAN97-83 F 434H mutant, Vero cells were transfected with the expression plasmids and treated
to pH pulses to promote fusion. Compared to the wild-type CAN97-83 (A2) F, the Q434H mutant
F induced dramatic syncytia formation in cells treated with PBS at pH 5, similar to TN83-1211 (B2)
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F (Fig. 9A and 9B). Quantification of fusion activity of the 434H mutant using a reporter gene assay
showed the same fusion activity of the mutant compared to TN83-1211 (B2) F, which is
significantly greater than that of wild-type CAN97-83 (A2) F at pH5 (Fig. 9C). Immunoprecipitation
to determine overall protein expression (Fig. 10A) and specifically surface expression (Fig. 10B) of
the proteins revealed similar expression levels (Fig. 10C). However, the cleavage efficiency of
surface F by exogenous trypsin was increased in CAN97-83 Q434H, which may contribute to the
hyperfusogenic phenotype (Fig. 10D). Further studies in surface expression and proteolytic
processing are necessary to determine if these factors, in addition to H434, contribute to the
fusion activity of this mutant. Altogether, these results show the introduction of an additional
histidine in this region of F, adjacent to histidine 435, resulted in greater overall fusion activity as
well as increased sensitivity to low pH to promote fusion.
The results of this study reveal significant differences in the fusion activity of F proteins
derived from diverse strains of HMPV that challenge the previous understanding the residues that
are involved in low pH triggered fusion for HMPV F. We identified a B2 clade HMPV F protein that
can be triggered to fuse by low pH, suggesting that this characteristic can be seen outside of clade
A viruses. High fusion activity promoted by low pH of TN83-1211 F was attributed to H434,
supporting that this region of F can contribute to the triggering of the conformational changes in
F to drive membrane fusion. Furthermore, TN94-49 (A2) F with K294 was triggered to fuse by low
pH, suggesting G294 is not an absolute requirement of clade A HMPV F for low pH-mediated
fusion. These findings demonstrate the complexity of HMPV F activity and regulation.
Discussion
In this study we characterized the fusion activity of the F derived from 3 different strains
of HMPV, TN94-49 (A2), TN96-12 (A1) and TN83-1211 (B2), compared to CAN97-83 (A2).
Treatment with low pH promoted fusion in cells expressing F proteins from three of the four
strains, with dramatic fusion observed by TN83-1211 (B2), whereas TN96-12 (A1) F failed to fuse
under standard assay conditions. The hyperfusogenic activity of TN83-1211 (B2) F was recreated
with the introduction of 434H in CAN97-83 (A2) F, supporting that this region of F plays a critical
role in low pH-induced triggering of membrane fusion.
We have previously reported low pH promoted membrane fusion by CAN97-83 (A2) F
(134, 136). However, others have reported that low pH does not promote fusion for strains
outside of the A clade (241, 242). Here we show low pH promoted fusion by an F protein from
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another A2 HMPV, TN94-49, as well as an F protein from the B2 clade, TN83-1211, suggesting low
pH promoted fusion activity is not exclusive to any phylogenetic group. The specific residue G294
has been reported as a requirement for low pH promoted fusion by clade A F proteins (241).
However, TN94-49 (A2) F, which fuses under low pH conditions, does not have this residue but
rather K294. Interestingly, genetic variability analysis of HMPV F revealed position 294 is one of
two positively selected sites in the gene, with relaxed selective constraints for amino acids G, K,
and E (324). This suggests the residue at this position, as long as it is G, K, or E, does not affect
virus fitness. Furthermore, it was reported that no lineage B HMPV F sequences have G294,
suggesting acidic pH is not a general trigger of HMPV F proteins for activity (241). In this study we
found TN83-1211 (B2) F does have the residue G294, indicating it is not exclusive to clade A
viruses. Additional residues at positions 296, 396, and 404 have also been shown to affect F
sensitivity to low pH (242). However, these positions are completely conserved in the F proteins
of the four strains analyzed here despite variable response to low pH (Fig. 6). Altogether, these
results suggest fusion protein activity is highly complex, and identification of specific residues
from prototype strains that are associated with low pH promoted fusion may be challenging.
Sequence analysis revealed TN83-1211 (B2) F is nearly identical to CAN97-83 (A2) F in
amino acid sequence, with a notable difference at position 434 in the hyperfusogenic protein. The
H434 residue lies adjacent to a conserved histidine at position 435, which has been shown to
participate in potential electrostatic interactions with surrounding positive residues K295, R396,
and K438, that drive the conformational change during triggering of the protein (243). We
generated a prefusion homology model for HMPV F (Fig. 11A) based on the solved crystal
structure of prefusion parainfluenza virus 5 F (222). Although the partial structure of the prefusion
form of HMPV F has been solved, it only includes residues to amino acid 430, and thus is lacking
the key residues examined in this study (221). Based on this model, H434 and H435, exposed on
the prefusion protein for solvent protonation, are surrounded by basic residues K295, R396, and
K438 (Fig. 11B). We propose the addition of a second histidine that can become protonated in
this critical region may contribute to lower prefusion stability due to charge-charge repulsion with
these surrounding basic residues (Fig. 11B), which is supported by the distribution of these
residues in the postfusion model (Fig. 11C).
Interestingly, examination of over 120 known HMPV F amino acid sequences revealed no
other HMPV F sequences with H434. This suggests a high level of fusion may not enhance fitness
of HMPV during endogenous infection. It has been shown for the attachment and fusion
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machinery of PIV3 that enhancement of receptor binding and fusion in monolayer cell culture is
detrimental to growth and replication in HAE culture and in cotton rats (325). Thus, some viruses
with high activity F are less competent to establish infection in an in vivo model. Alternatively,
mutant RSV with F proteins of high fusion activity caused higher viral loads, severe lung
histopathology, and weight loss in mice compared to controls (326). Therefore, the impact of
fusion activity on viral fitness may depend on complex factors beyond the fusion protein alone.
Because H434 is not found in any other known F from HMPV aside from TN83-1211 (B2), it is
possible hyperfusogenic activity does not confer a fitness advantage in the population HMPV.
Under standard syncytia and reporter gene assay conditions, TN96-12 (A1) F failed to fuse
at low or neutral pH despite surface expression and processing equivalent to other variants
analyzed. These results suggest that TN96-12 (A1) F requires additional cellular or viral factors to
trigger fusion activity that are not present at the plasma membrane. It has recently been shown
HMPV can fuse in endosomes, which may have host factors available to trigger F that are not
present at the plasma membrane (282). While F protein activity independence from an
attachment protein has been characterized for CAN97-83 (A2) F (134), it is possible TN96-12 (A2)
F requires interaction with other viral proteins that are not present in these fusion assays. It has
been shown HMPV G can affect particle entry in dendritic cells (93) and also the small hydrophobic
protein can also modulate fusion activity (92). Lastly, existing methodologies to study HMPV F
limit detection of specific prefusion and postfusion conformations. Therefore, TN96-12 (A1) F
when solely expressed at the plasma membrane without other viral glycoproteins may be
unstable in its prefusion form and prematurely trigger resulting in the absence of fusion activity.
HMPV F fusion activity is a true balancing act between prefusion stability and triggering
of F to fuse membranes and establish infection. Tipping too far in either direction appears to be
a detriment to viral fitness. The results in this study highlight the diversity in HMPV F activity in
response to low pH and the challenges of identifying specific residues that correlate with low pH
promoted fusion. Further studies are necessary that take into account the complex regulatory
interactions in the context of an intact infectious viral particle.
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Figure 5. HMPV F proteins from different strains exhibit variable fusion activity promoted by
low pH.
(A) Representative images of syncytium formation of cells expressing the HMPV F proteins after
pulses at pH 5 or pH 7 (n = 3). (B) The fusion index was calculated using the equation f = [ 1 – ( C /
N ) ] where c is the number of cells in a field after fusion and n the number of nuclei. Six fields
were scored per condition representative of 3 independent experiments. * Indicates statistically
significant compared to f for CAN97-83 (A2) F after pH 5 pulses, ** Indicates statistically significant
compared to f for CAN97-83 (A2) F after pH 7 pulses (n=3) (C) Luciferase reporter gene assay of
Vero cells transfected with HMPV F that were used to overlay BSR cells and subjected to two pH
pulses. Data are presented as percentages of CAN97-83 (A2) F luminosity (fusion) at pH 5 (n = 3)
+/- standard deviation. * Indicates statistically significant compared to f for CAN97-83 (A2) F after
pH 5 pulses.
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Figure 6.Amino acid sequence of F proteins of CAN97-83 (A2), TN94-49 (A2), TN96-12 (A1), and
TN83-1211 (B2).
Sequence alignment was generated using ClustalW. The asterisk “*” indicates identical residues,
“:” indicates conserved substitutions and “.” semi-conserved substitutions.
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Figure 7.HMPV F protein expression and cleavage by exogenous trypsin.
Representative gel of (A) total and (B) surface protein expression in metabolically labeled Vero
cells expressing CAN97-83 (A2) F, TN94-49 (A2) F, TN96-12 (A1) F, and TN83-1211 (B2) F. (C)
Quantification of the total and surface expression of the F0 form in metabolically labeled Vero
cells expressing CAN97-83 (A2) F, TN94-49 (A2) F, TN96-12 (A1) F, and TN83-1211 (B2) F. Data are
presented as percentages of CAN97-83 (A2) F expression, which was set to 100% (n = 3). (D)
Trypsin cleavage efficiency of surface expression of CAN97-83 (A2) F, TN94-49 (A2) F, TN96-12
(A1) F, and TN83-1211 (B2) F in the presence or absence of 0.3 μg/ml of TPCK-trypsin was
quantified by the following equation: percent cleavage = F1/(F1 + F0) (n= 3). Error bars show
standard deviation.
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Figure 8. Partial protein sequence analysis of F from 4 strains of HMPV surrounding key residues
at positions (A) 294 and (B) 435.
Sequence alignment was generated using ClustalW. The asterisk “*” indicates identical residues
and “:” indicates conserved substitutions.

43

Figure 9. Q434H mutation results in hyperfusogenic activity in CAN97-83 F promoted by low pH.
(A) Representative images of syncytium formation of cells expressing the HMPV F proteins after
pulses at pH 5 or pH 7 (n = 3) (B) The fusion index was calculated using the equation f = [ 1 – ( C /
N ) ] where c is the number of cells in a field after fusion and n the number of nuclei. Six fields
were scored per condition representative of 3 independent experiments. * Indicates statistically
significant compared to f for CAN97-83 (A2) F after pH 5 pulses (n = 3) (C) Luciferase reporter gene
assay of Vero cells transfected with HMPV F that were used to overlay BSR cells and subjected to
two pH pulses. Data are presented as percentages of CAN97-83 (A2) F luminosity (fusion) at pH 5
(n = 3) +/- standard deviation. * Indicates statistically significant compared to f for CAN97-83 (A2)
F after pH 5 pulses, ** indicates statistically significant compared to f for CAN97-83 (A2) F after
pH 7 pulses.
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Figure 10. Mutant F protein expression and cleavage by exogenous trypsin.
Representative gel of (A) total and (B) surface protein expression in metabolically labeled Vero
cells expressing CAN97-83 (A2) F, TN83-1211 (B2) F and mutant CAN97-83 Q434H F. (C)
Quantification of the total and surface expression of the F0 form in metabolically labeled Vero
cells expressing CAN97-83 (A2) F, TN83-1211 (B2) F and mutant CAN97-83 Q434H F. C. Data are
presented as percentages of CAN97-83 (A2) F expression, which was set to 100% (n = 3). (D)
Trypsin cleavage efficiency of surface expression of CAN97-83 (A2) F, TN83-1211 (B2) F and
mutant CAN97-83 Q434H F in the presence or absence of 0.3 μg/ml of TPCK-trypsin was calculated
with the following equation: percent cleavage = F1/(F1 + F0) (n= 3). Error bars show standard
deviation.
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Figure 11. HMPV F structure homology models highlighting key residues surrounding H435.
(A) The amino acid sequence of HMPV F was threaded onto the crystal structure of PIV5 F in its
metastable prefusion form (222). In a model of the HMPV F prefusion conformation (B) residues
H434 and H435 are exposed on the surface of the globular region of the protein and are
surrounded by basic residues K295, R396, and K438 in close proximity. (C) The postfusion
homology model of HMPV F was created by threading the amino acid sequence of HMPV into the
crystal structure of Newcastle Disease Virus F in its postfusion conformation (317). In the
postfusion homology model of HMVP F, the basic residues are no longer located as close proximity
to H434 and H435.
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Chapter 4: Inhibition of HMPV infection by blocking binding to heparan sulfate
*E. coli K5 polysaccharide derivatives were supplied by David Lembo (Department of Clinical and
Biological Sciences, University of Turin, S. Luigi Gonzaga Hospital, 10043, Orbassano, Turin, Italy)
and Pasqua Oreste (Glycores 2000 S.r.l. 20155 Milan, Italy). The human airway epithelium (HAE)
tissue experiments using PIV5 and a single experiment using HMPV with iota-carrageenan
treatment were completed by Stacy E. Smith.
Introduction
Acute viral respiratory tract infection is the most frequently observed illness in humans
worldwide (327). Human metapneumovirus (HMPV), an enveloped, negative-sense, singlestranded RNA virus in the Paramyxoviridae family, is a common cause of both upper and lower
respiratory tract infections (30, 31, 321). First identified in 2001 in the Netherlands, HMPV is now
known to be the cause of respiratory infections in humans since at least 1958 (31). Nearly every
person is exposed to HMPV in the first decade of life; sero-conversion occurs on average by the
age of five, and nearly 100% of individuals test seropositive for antibody reactivity to HMPV
antigens by the age of ten (7). In children, HMPV infection is the second most common cause of
hospitalization due to respiratory infection after the closely related respiratory syncytial virus
(RSV) (37, 38). While infants are considered the most vulnerable population to illness from HMPV,
adults can foster severe respiratory disease as well, especially the elderly, immunocompromised
patients, and individuals with chronic underlying diseases (43-45). In addition to upper respiratory
involvement with symptoms typically associated with the common cold, HMPV infection can
result in serious lower respiratory syndromes such as pneumonia, bronchitis, and bronchiolitis
(321, 322). Due to the recent ability to routinely detect this virus through the inclusion of HMPV
in multiplex detection assays, HMPV has been associated with disease outside of the respiratory
tract in some cases, including viral encephalopathy (62, 64, 328) and acute myocarditis (69), from
initial respiratory involvement. Despite this tremendous clinical burden, there is no known vaccine
to prevent HMPV infection, and treatment options are limited to administering ribavirin, which
does not have established efficacy against HMPV infection (329).
Key features of HMPV entry into target cells to establish infection have been
characterized recently. HMPV utilizes heparan sulfate (HS) present on the cell surface to bind to
47

target cells (79), followed by clathrin-mediated endocytosis and membrane fusion in endosomes
(282). HS is a negatively charged polysaccharide belonging to the family of glycosaminoglycans
composed of repeating disaccharide units formed by glucosamine and glucuronic acid, which can
undergo a series of modifications during the biosynthesis, leading to very heterogeneous chains.
In HS the glucosamine can be N-acetylated, or N-sulfated and O-sulfated in various positions and
to varying degrees. Glucuronic acid can also be modified by epimerization. Additionally, integrin
αVβ1 has also been shown to play a role for efficient HMPV entry (79, 119) and has been proposed
to be involved in attachment (120).
HSPGs have been implicated in virus-cell interactions for other enveloped viruses,
including RSV (163, 330, 331), human papilloma virus (HPV) (162), herpes simplex virus (HSV) (173,
174, 177, 332), human immunodeficiency virus (HIV) (159, 161, 169), and others (reviewed in
(333)). We have previously shown that nearly complete reduction in binding and infection results
when HS is removed from the cell surface using heparinases, while cells that are able to synthesize
only HS, and not any other GAGs, are fully able to bind HMPV (79). Unlike other paramyxoviruses
that require two distinct viral glycoproteins to mediate attachment and binding, the fusion protein
(F) of HMPV is sufficient for binding and infection (76, 77, 136). Recombinant HMPV that does not
have the attachment protein (G) or small hydrophobic protein (SH) is able to bind cells at wildtype levels via HS (79). Thus, the putative interaction between the HMPV F and HS provides an
opportunity for antiviral development.
In this study, we describe the potent anti-HMPV effects of the sulfated polysaccharide,
iota-carrageenan, in models of respiratory epithelial cells and polarized airway tissues, indicating
that the HS-F interaction is important in physiologically relevant models. To further characterize
structural features of HS important for binding by HMPV F, we utilized a mini-library of variably
sulfated derivatives of Escherichia coli K5 polysaccharide, which revealed that the critical common
feature required for effective inhibition of binding and infection, is the O-sulfation. In addition,
we showed that occluding heparan sulfate with peptide dendrimer SB105-A10 inhibits the binding
interaction between HMPV F and target cells and airway tissues. These results provide critical
support for a role for HS-HMPV F protein interactions in physiologically relevant models, and
identify key features of the interaction between HMPV and HS that have implications for infection
in vivo and may serve for antiviral development.
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Results
Iota-carrageenan inhibits HMPV infection in human respiratory cells
We have previously shown that specific removal of cell surface HS (Fig. 12A) inhibits
HMPV binding and infection in a number of cell types (79). In addition, CHO cell lines with altered
GAG metabolism were used to further demonstrate that HMPV specifically requires HS for
infectivity (79). To dissect how interaction with HS regulates HMPV infection in physiologically
relevant models and to determine if blocking this interaction could be a potential antiviral
approach, we utilized a sulfated polysaccharide, heparan sulfate mimetics and a compound that
occludes HS in combination with infection studies in human bronchial epithelial cells (BEAS-2B) or
human airway epithelial (HAE) models.
Sulfated polysaccharides have been previously employed to target viral infection,
including a number of studies with carrageenans, which are isolated from red seaweed (334).
Carrageenans are composed of sulfated repeating galactose units (Fig. 12B). The three types of
known carrageenans (iota, lambda, and kappa) differ in number and positions of sulfate groups
(reviewed in (334)). Carrageenans have shown antiviral activity against a number of viral
pathogens, including human papilloma virus (HPV) (335), HIV (336), dengue virus (337) and
influenza A virus (338). Importantly, iota-carrageenan (Fig. 12B) has been used safely in human
trials in the form of a nasal spray to reduce viral infection (339-341).
To verify that sulfated polysaccharides would inhibit HMPV infection in a relevant cell
culture model, we first determined the anti-HMPV activity of iota-carrageenan, a well
characterized sulfated polysaccharide that has been shown to inhibit infection of other viruses
that bind heparan sulfate. Infection of BEAS-2B cells was performed using a recombinant HMPV
(strain CAN97-83, clade A2) that results in green fluorescent protein (GFP) expression upon viral
infection, which was quantified by flow cytometry. Pretreatment of HMPV with iota-carrageenan
resulted in inhibition of infection, with nearly a complete reduction in infection achieved with 10
µg/mL of iota-carrageenan (Fig. 13A and 13C). To determine if iota-carrageenan had a nonspecific
antiviral effect, the paramyxovirus parainfluenza virus 5 (PIV5), which does not utilize heparan
sulfate for binding, was used. Incubating rgPIV5, a recombinant PIV5 virus that results in GFP
expression, with iota-carrageenan prior to infection did not inhibit infection of BEAS-2B cells at
any of the concentrations used compared to the untreated control (Fig. 13B and 13C).
Furthermore, treatment of BEAS-2B cells with the highest concentration of iota-carrageenan
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tested in the infection assays did not reduce cell viability, as measured by 3-(4, 5-Dimethylthiazol2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) cell viability assay (Fig. 14A). Similar effects of
iota-carrageenan on rgHMPV and rgPIV5 infection were observed in Vero cells (data not shown).
These results indicate that HS-HMPV interactions are critical in BEAS-2B cells, and that iotacarrageenan has anti-HMPV activity, most likely attributed to its sulfated structure.
Our previous studies suggested that HMPV binds to heparan sulfate via the F protein, and
we hypothesized that iota-carrageenan is inhibiting HMPV infection by competing with HS binding
sites located in HMPV F. To test this, HMPV was added to BEAS-2B cells at 4°C, allowing for binding
to occur but not infection, and the amount of bound virus was quantified by detection of the
HMPV matrix protein present in cell lysates with β-actin as a loading control, by Western blot.
Pretreating HMPV at an MOI of 1 with 40 µg/mL carrageenan for 30 mintes at 4°C prior to addition
to the cells resulted in about 85% inhibition of particle binding, compared to the untreated control
(Fig. 13D and 13E), demonstrating that iota-carrageenan competes with the binding of HMPV to
HS. Of the three glycoproteins in the viral envelope of HMPV, the attachment protein G, small
hydrophobic protein SH, and F, only F is required by HMPV to be infectious; recombinant HMPV
without G or SH, HMPV ΔG and ΔGΔSH respectively, are able to bind cells at wild-type levels (79)
and are replication competent in a nonhuman primate model of infection (77). To test whether
iota-carrageenan inhibition of HMPV binding and infection is dependent exclusively on F, we
pretreated the recombinant HMPV ΔG and ΔGΔSH with iota-carrageenan and determined the
effects on overall infection and binding in BEAS-2B cells. Iota-carrageen inhibited HMPV ΔG and
ΔGΔSH binding to a similar degree as wild-type HMPV (Fig. 13D and 13E), which supports the
hypothesis that interaction between HMPV and heparan sulfate is mediated by F. Interestingly,
ΔG and ΔGΔSH HMPV binding to BEAS-2B cells was more efficient than WT HMPV, as a greater
fraction of input particles of ΔG and ΔGΔSH HMPV bound to BEAS-2B cells than WT HMPV. The
input for all three virus samples was determined for each experiment, and was not statistically
different across all binding assays completed (data not shown). The potential role of G and SH in
regulating HMPV binding is further addressed in Chapter 5. However, despite increased binding
at baseline, iota-carrageenan did inhibit binding of ΔG and ΔGΔSH HMPV to the same degree as
WT HMPV, leading to the conclusion that F mediates the interaction with HS (Fig. 13E).
The results in a monolayer respiratory cell model support the hypothesis that HMPV F
mediates a key binding interaction to heparan sulfate, and this event can be inhibited using the
highly sulfated polysaccharide, iota-carrageenan. However, a monolayer cell culture model is
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limited in the ability to recapitulate the complex features of the respiratory epithelium, which
include moving cilia, mucus, distinct cell types with important physiological roles, and polarity
maintained by tight junctions. Furthermore, immortalized cells highly express HSPGs in a pattern
that may be different than complex organized tissues found in vivo, and immunohistochemistry
studies have not detected significant amounts of HS on the apical surface of human airway, raising
concerns that HS interactions may be less important in an airway model (143). We therefore
examined the effect of sulfated polysaccharides in a polarized human airway tissue model (HAE;
MatTek) that more closely recapitulates the complexity of the human airway, which is the primary
site of HMPV infection. HAE tissues have been previously used as models of respiratory virus
infection, including human parainfluenza virus 3 (325), rhinovirus (342), human bocavirus 1 (343),
and RSV (307).
To test whether iota-carrageenan inhibits HMPV infection in the HAE model, iotacarrageenan treated rgHMPV was used to inoculate the apical surface of the HAE tissues, and a
significant reduction in infection of approximately 75% was observed (Fig. 13F and 13G). Unlike
rgHMPV, treatment of rgPIV5 with iota-carrageenan had no effect on infection in the airway
tissues (Fig. 13F and 13G). These findings indicate that HMPV interactions with heparan sulfate
are also important in complex polarized airway tissues that histologically resemble the human
respiratory tract, and support the hypothesis that HMPV requires heparan sulfate to establish
infection at the apical surface of the respiratory epithelium.
O-sulfated K5 polysaccharide derivatives inhibit HMPV infection
While our preliminary results strongly support a key role for HS in HMPV infection, the
specific features of HS required remain to be determined. A class of molecules mimicking HS and
thus possible inhibitors of heparan sulfate-virus interactions is represented by the sulfated
derivatives of the Escherichia coli capsular K5 polysaccharide (Fig. 12D). K5 polysaccharide
derivatives are heparan-like molecules devoid of anticoagulant activity obtained by the sulfation
of the E. coli capsular K5 polysaccharide that has the same structure of the biosynthetic precursor
of HS, N-acetyl heparosan. A small library of derivatives with different degrees of sulfation has
been synthesized using chemical and enzymatic modifications (318). Sulfated K5 derivatives have
been shown to inhibit infection in other viruses in a specific manner , including HPV (335), RSV
(344), Dengue (345), CMV (346), HSV-1 and HSV-2 (347), and HIV (348). Analysis of the anti-HMPV
activity of these compounds can therefore be used to identify structural features that are
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important for recognition by HMPV F and potentially help to identify a potent heparan sulfate
mimic.
Because heparan sulfate is negatively charged due to sulfate modifications on the
disaccharide units, we hypothesized that charge-charge interactions are contributing to the
binding between F and this polysaccharide. Therefore, we predicted that the most highly sulfated
K5 derivatives, mainly K5-N,OS(H), and K5-OS(H), would have the greatest inhibitory effect on
HMPV infection. To test this, rgHMPV at an MOI of 1 pretreated with the derivatives at 1μM was
used to inoculate BEAS-2B cells. As predicted, the highly sulfated K5 derivatives, K5-N,OS(H), and
K5-OS(H), dramatically inhibited infection (Fig. 15A). Among the lower sulfated derivatives, K5 and
K5-NS did not have an observable effect on HMPV infection when examined by microscopy (Fig.
15A), while K5-N,OS(L) and K5-OS(L), also inhibited HMPV infection dramatically (Fig. 15A). K5-NS,
which has a single N-linked sulfate group in position 2 of glucosamine, had no effect on HMPV
infection (Fig. 15A), indicating a key role of O-sulfate groups in the observed inhibition. When
HMPV was treated with variable concentrations (10nm to 1μM) of the K5 derivatives and used to
infect BEAS-2B cells, flow cytometry analysis of infected cells revealed a dose dependent
inhibition of HMPV infection by all the O-sulfated K5 derivatives (Fig. 15B). K5-NS had no effect
on HMPV infection, while some inhibition resulted from K5, although only at the highest
concentration (Fig. 15B). The reduction of infection by the K5 polysaccharide was not expected,
and the mechanism of this action remains unclear as it did not affect HMPV binding (Fig. 15D and
15E). None of the K5 polysaccharide derivatives had an effect on PIV5 infection (Fig. 15C).
Additionally, treatment of BEAS-2B cells with the 10 µM of K5 polysaccharide derivatives, the
concentration used in HAE infection experiments and 10-fold higher than the highest
concentration used in cell infection assays, did not reduce cell viability, as measured by MTT cell
viability assay (Fig. 14A). To determine whether the K5 compounds inhibit HMPV infection by
competition, the same binding assay as described in the carrageenan studies was used. rgHMPV
was treated with 1 µM of each of the K5 polysaccharide derivatives prior to incubation with BEAS2B cells at 4°C at an MOI of 1 to allow for binding to take place. While unmodified K5 and K5-NS,
which has a single N-linked sulfation modification, had no effect on viral binding, the higher
sulfated compounds, K5-N,OS(L) and K5-OS(L), and the highly sulfated compounds K5-N,OS(H),
and K5-OS(H), reduced HMPV binding to BEAS-2B cells significantly (Fig. 15D and 15E).
To confirm these findings in a physiologically relevant tissue model, we determined the
effect of K5-N,OS(H) and K5-OS(H), which had the greatest inhibition of HMPV infection in
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monolayer cells, in polarized airway tissues. HAE tissues were infected at the apical surface with
rgHMPV at an MOI of 5 pretreated with 10µM K5-N,OS(H) or K5-OS(H), or Opti-MEM. Forty-eight
hours post-infection, we observed a dramatic reduction in infected cells at the apical surface (Fig.
16A). Quantification of GFP-expressing cells revealed approximately a 70% reduction in HMPV
infection compared to the control (Fig. 16B). Taken together, these data suggest that highly
sulfated K5 derivatives effectively inhibit binding and infection of HMPV, and that O-sulfation is
an important structural feature required for the interaction to occur, and strongly support the
hypothesis that HMPV interaction with HS plays a significant role during apical infection.
Heparan sulfate occlusion inhibits HMPV infection and binding
We have shown that HMPV F mediates a binding interaction to HS that can be inhibited
both in cell culture and tissue models using iota-carrageenan and a small library of K5
polysaccharide derivatives. As an alternative mechanism to characterize the interaction between
HMPV and HS, we examined the effect of blocking HS moieties on the target cell, thus making
heparan sulfate unavailable for binding. There is two-fold logic to investigating the effect of a
heparan sulfate-occluding compound on HMPV binding. Removal of HS caused a robust block in
HMPV infection (79); however, HSPGs have critical constitutive and induced interactions with
other cellular proteins (reviewed in (349)), and removing HS may interrupt these interactions,
causing cellular changes. HS occluding compounds that prevent further ligand binding are less
likely to disrupt preexisting HS interactions, and therefore, serve as an alternative approach to
address the direct interaction of HMPV with HS. Furthermore, a compound that occludes HS and
inhibits HMPV infection may serve as potential building block for antiviral development for HMPV
and other viruses that are known to bind HS.
To accomplish this, we utilized a previously characterized heparan sulfate occluding
compound, peptide dendrimer SB105-A10 (139, 307, 350). Peptide dendrimers, branched
synthetic molecules which consist of a peptidyl branching core and covalently attached surface
peptide units, have a number of potential applications, especially in relation to the development
of antiviral agents. The peptide dendrimer SB105-A10 (Fig. 12C), which has a branched peptide
core with clusters of basic residues that bind to negatively charged sulfate and carboxyl groups,
has been shown to specifically occlude ligand binding from HSPGs (139, 350). Furthermore,
SB105-A10 has previously been reported to exhibit antiviral activity against RSV (307), CMV (350),
HIV (139), HPV (351), HSV-1 and HSV-2 (352), as well as some filoviruses (170).
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To determine if SB105-A10 reduces HMPV infection in human lung epithelial cells, BEAS2B cells were treated with SB105-A10 at 1µM prior to infection with rgHMPV at an MOI of 1 and
cells were imaged 24 hours later for GFP expression; rgPIV5 was used in control studies to
determine specificity. SB105-A10 treatment resulted in dramatic inhibition of HMPV infection,
whereas PIV5 infection was not reduced (Fig. 17A). We performed quantification of the effects of
SB105-A10 on rgHMPV or rgPIV5 infection by flow cytometry for GFP expression 24 hr postinfection. In these experiments both BEAS-2B and A549 cells were used to determine if the effect
of SB105-A10 is cell type-dependent, as this compound is mediating its effects by interacting with
the target cell. In BEAS-2B cells, a dose-dependent inhibition of approximately 70% of rgHMPV
infection resulted with SB105-A10 treatment, whereas rgPIV5 infection was not affected (Fig.
17B). Similar results were seen in A549 cells (Fig. 17C). Additionally, treatment of BEAS-2B cells
with the 2 µM of SB105-A10, the concentration used in HAE infection experiments and 2-fold
higher than the highest concentration used in cell infection assays, did not reduce cell viability, as
measured by MTT cell viability assay (Fig. 14B). Based on our hypothesis of HMPV attachment, we
predicted that SB105-A10 inhibits infection by blocking particle binding, specifically by preventing
the interaction between heparan sulfate and F. To address this, we utilized a binding assay with
WT HMPV, ΔG HMPV, and ΔGΔSH HMPV to determine the effects of SB105-A10. BEAS-2B cells
were treated with 1µM SB105-A10 or Opti-MEM prior to addition of HMPV at an MOI of 1. The
cells were incubated at 4°C for 2 hr to allow for binding and then cell lysates were analyzed for M
by Western blot to determine binding. A significant reduction of viral binding was observed in WT
HMPV and the recombinant ΔG HMPV and ΔGΔSH HMPV with SB105-A10 treatment (Fig. 17D and
17E). As was observed in binding assays with iota-carrageenan (Fig. 13D), greater baseline binding
was observed for ΔG HMPV and ΔGΔSH HMPV compared to WT (Fig. 17D), although the same
levels of reduction in binding were observed with SB105-A10 (Fig. 17E). To determine the effect
of SB105-A10 in polarized tissues, the apical surface of HAE tissues was treated with SB105-A10
at 2µM prior to infection with rgHMPV at an MOI of 5. Treatment with SB105-A10 resulted in a
reduction of infected cells 48 hours post-infection (Fig. 18A). Quantification of infected cells
revealed greater than 50% reduction in HMPV infection at the apical surface with SB105-A10
treatment, compared to vehicle treated control tissues (Fig. 18B). Altogether, these results
indicate that occlusion of HS moieties on target cells inhibits HMPV binding and infection
mediated by HMPV F and further support that HS is available for viral binding at the apical surface
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of the airway. Furthermore, based on our results, occlusion of HS could potentially be used as an
antiviral strategy against HMPV.
Discussion
Heparan sulfate is a key attachment factor for HMPV binding to the cell surface. In this
study we used compounds that modulate the attachment event to characterize the interaction
between HMPV and HS. Our results support a model (Fig. 19) where HMPV F mediates a direct
binding interaction to HS, which can be inhibited by sulfated polysaccharides, specifically sulfated
in O-position (Fig. 15), and HS occluding compounds (Fig. 17). Our results further indicate that HS
in the airway epithelium serves as a binding factor during infection at the apical surface, and
suggest that HS modulating compounds may serve as a platform for potential HMPV antiviral
development.
Iota-carrageenan treatment of HMPV resulted in inhibition of attachment (Fig. 13D) and
infection (Fig. 13A and 13C) in bronchial epithelial cells and polarized airway tissues (Fig. 13F). The
anti-HMPV activity of a sulfated polysaccharide has been previously reported using native and
depolymerized galactans isolated from the red seaweed Cryptonemia seminervis (353). While
iota-carrageenan is a highly heterogeneous polysaccharide with regard to size, it is unclear if its
molecular weight is important in the inhibition of the viral interaction with heparan sulfate. It has
been shown that depolymerized galactans ranging in molecular weights from 52-64 kDa were able
to inhibit HMPV infection as well as the intact polysaccharide, suggesting low molecular weight
sulfated polysaccharides can have potent antiviral activity (353). The potent anti-HMPV effect of
iota-carrageenan on HMPV infection in both cells and tissue models has potential as a respiratory
therapy, especially as iota-carrageenan has been shown to be safe to use in humans (338, 341,
354). Iota-carrageenan application in the form of a nasal spray in a randomized clinical trial
showed reduction in viral titers and fewer days of symptomatic illness (341). Its efficacy to
specifically reduce HMPV infection in humans remains to be determined.
To better understand the structural features of heparan sulfate required for recognition
by HMPV, we used a mini-library of variably sulfated heparan-like K5 polysaccharide derivatives.
Interestingly, our results highlight that variations in the structure of the K5 derivatives, namely
the position and degree of sulfation, can modulate the selectivity and potency of their activities
against HMPV (Fig. 15B). The highly sulfated K5 polysaccharides exhibited the greatest inhibition
of HMPV infection, suggesting negative charges play a role in interacting with F (Fig. 15B). The
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highly sulfated K5-OS(H) and K5-N,OS(H) have been shown to inhibit Dengue virus attachment to
microvascular endothelial cells by interacting with the viral envelope protein, as shown by surface
plasmon resonance (SPR) analysis using the receptor-binding domain III of the E protein (345).
Our results support the model that HMPV binding to HS mediated by F involves charge-charge
interaction, possibly by a cluster of exposed positively charged residues on F. This is demonstrated
by the very high inhibitory activity exerted by K5-OS (H) (Fig. 15B, 15D and 15E). This finding
suggests the interaction between HMPV F and HS depends on a specific sulfation pattern, rather
than overall negative charges alone. Since the N-sulfated K5 derivatives are less effective in
inhibiting the binding of HMPV, we can conclude that O-sulfate groups are important for HMPV
F-HS interactions. Interestingly, the most effective fractions of depolymerized galactans to inhibit
HMPV infection have the sulfate modifications principally on C-2 and C-6 of the galactose sugars
(353). These results further support the importance of O-sulfate groups inhibiting the HS
interaction with HMPV F and also suggest that the sugar backbone of the polysaccharide is not
the main determinant of the antiviral activity.
Interestingly, binding experiments in this study demonstrated a greater affinity of ΔG and
ΔGΔSH HMPV to bind BEAS-2B cells than WT HMPV (Fig. 13D and 17C), as the untreated control
bands consistently showed higher levels of particle binding for the recombinant viruses compared
to the WT, despite equivalent number of particles added to the cells. We have previously reported
that the ΔG and ΔGΔSH recombinant viruses bind and infect at WT levels in other cell types,
suggesting that there may be cell-type specific differences in binding. Taken together, these
results suggest that SH and G negatively modulate binding in BEAS-2B cells, and thus their absence
results in more efficient particle binding. Both HMPV SH and G have been previously reported to
modulate events in HMPV entry. Our group has shown SH can modulate fusion activity of F (92).
Furthermore, HMPV G and SH have been previously shown to negatively modulate HMPV entry,
as particle uptake by micropinocytosis in dendritic cells is enhanced for recombinant HMPV
lacking G and SH (93). However, the mechanisms by which G and SH modulate these critical early
steps remain to be elucidated.
Treating the cells and tissues with SB105-A10, which specifically occludes any ligand
binding to HSPGs, resulted in a significant inhibition of HMPV binding and infection. Our results
further support the model that HMPV uses HS as an attachment factor due to a direct binding
interaction with F. While adhered immortalized cells readily express accessible heparan sulfate, it
is less clear where heparan sulfate localizes in the respiratory epithelium in vivo. Based on
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detection by immunohistochemistry of human epithelial tissue, heparan sulfate has been
previously hypothesized to localize exclusively to the basolateral epithelium (143), making it
unclear how a respiratory virus would access heparan sulfate to infect apically. The results in this
study demonstrate that HMPV can infect polarized airway tissues at the apical surface and that
HS-occlusion inhibits this apical infection, suggesting HS is found at sufficient levels to promote
attachment at the apical surface of the airway. HS occlusion with SB105-A10 has also been shown
to inhibit RSV infection at the apical surface of HAE tissues (307). HS modification is found on a
number of transmembrane proteins, and the two main protein families with HS are syndecans
and glypicans. Syndecans have been shown to serve as receptors for other HS-binding viruses,
including hepatitis C (172), dengue virus (168) and HIV (161). Anti-syndecan-1 antibodies have
recently been shown to block RSV infection at the apical surface of human airway epithelium
cultures (355). The role of a specific HSPG, such as one of the syndecan proteins, in HMPV
infection remains to be determined, but our results strongly indicate that sufficient levels of HS
on HSPGs are exposed at the apical surface of the airway epithelium for viral infection, including
HMPV.
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Figure 12. Representative structures of heparan sulfate and related compounds.
(A) Heparan sulfate disaccharides modified by the following possible substitutions: Ac – acetyl, R=
H or SO3-, R’ = H, Ac, or SO3-. Structures adapted from (349). (B) Iota-carrageenan adapted from
(334) (C) SB105-A10 (D) K5 polysaccharide derivatives.
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Figure 13. Iota-carrageenan inhibits HMPV infection in cells and tissues by blocking binding.
(A) BEAS-2B cells infected with rgHMPV at an MOI of 1 was treated with variable concentrations
of iota-carrageenan. Cells were imaged 24 HPI. (B) BEAS-2B cells were infected with rgPIV5 at an
MOI of 1 treated with 40 µg/mL of iota-carrageenan or vehicle. Cells were imaged 24 hours post
infection (HPI). (C) Quantification of rgHMPV and rgPIV5 infection in BEAS-2B cells using flow
cytometry to detect GFP expressing cells 24 HPI. Data presented as a percent infection of the
untreated control (0 µg/mL) for each virus. Data points are means (+/- SD) of duplicate
measurements and are representative of a minimum of 3 independent experiments. * Indicates
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statistical significance of P< 0.0001. (D) HMPV viruses (WT and recombinant mutants ΔG and
ΔGΔSH) were treated with vehicle or 40 µg/mL of iota-carrageenan and added to BEAS-2B cells at
an MOI of 1 at 4°C for particle binding. Lysates of washed cells were analyzed for HMPV binding
by Western blot analysis for M. Input represents 5% of WT HMPV added to the cells for binding.
No virus was added to mock infected cells. β-actin served as a loading control. (E) Band intensities
of the matrix protein and β-actin were determined for untreated and treated (40 µg/mL iotacarrageenan) samples. The data are reported as a ratio of M to β-actin normalized to the
untreated control for each virus. Data points are means (+/- SD) of measurements representative
of 7 independent experiments. * Indicates statistical significance of P< 0.0001. (F) HAE tissues
were infected with rgHMPV or rgPIV5 at an MOI of 5 treated with 40 µg/mL of iota-carrageenan
or vehicle and imaged 48 hours post-infection at 5X magnification. (G) Quantification of HAE tissue
infection. Data points are means (+/- SD) of triplicate measurements and are representative of
minimum 3 independent experiments of HMPV infection (rgPIV5 data representative of a single
HAE experiment). * Indicates statistical significance of P< 0.0001 using Bonferroni’s Multiple
Comparison Test (Prism).
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Figure 14. Iota-carrageenan, SB105-A10 and K5 derivatives do not reduce cell viability.
(A) BEAS-2B cells were treated with 40 µg/mL of iota-carrageenan, 10 µM of each of the K5
polysaccharide derivatives, or vehicle (untreated) in triplicate and assayed for viability by MTT cell
viability assay according to manufacturer’s protocol. (B) BEAS-2B and A549 cells were treated with
2 µM of SB105-A10 or vehicle (untreated) and assayed for viability by MTT assay. Absorbance at
590 nm is normalized to untreated control. Data points are means (+/- SD) of triplicate
measurements and are representative of 3 independent experiments.
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Figure 15. O-sulfated K5 polysaccharide derivatives inhibit HMPV infection in BEAS-2B cells by
competing for binding.
(A) BEAS-2B cells were infected with rgHMPV at an MOI of 1 treated with 1 µM of each K5
polysaccharide derivative or vehicle. Cells were imaged 24 hours post-infection. BEAS-2B cells
were infected with rgHMPV (B) or rgPIV5 (C) at an MOI of 1 treated with 10 nM, 100 nM, or 1 µM
of each K5 polysaccharide derivative or vehicle. Infection was quantified by flow cytometry to
detect GFP expressing cells 24 HPI. The data is presented as a percent infection of the untreated
control. Data points are means (+/- SD) of duplicate measurements and are representative of a
minimum of 3 independent experiments. Statistically, * and ** indicate significance of P< 0.01
and P<0.0001, respectively. (D) WT HMPV was treated with vehicle (untreated) or a K5
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polysaccharide derivative at 1 μM and added to BEAS-2B cells at an MOI of 1 at 4°C for particle
binding. Lysates of washed cells were analyzed for HMPV binding by Western blot analysis for M.
No virus was added to mock infected cells. β-actin served as a loading control. (E) Band intensities
of the matrix protein and β-actin were determined for untreated and treated (1 μM) samples. The
data are reported as a ratio of M to β-actin normalized to the untreated control for each virus.
Data points are means (+/- SD) of measurements representative of 5 independent experiments. *
Indicates statistical significance of P< 0.001, and ** indicates statistical significance of P< 0.0001
using Bonferroni’s Multiple Comparison Test (Prism).
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Figure 16. Highly sulfated K5 polysaccharide derivatives inhibit HMPV infection in HAE.
(A) HAE tissues were infected with rgHMPV at an MOI of 5 treated with 10 µM K5-N,OS(H) or K5OS(H), or vehicle (untreated) and imaged 48 HPI at 5X magnification. (B) Quantification of HAE
tissue infection. Data points are means (+/- SD) of triplicate measurements and are representative
of a minimum of 3 independent experiments. * Indicates statistical significance of P< 0.0001 using
Bonferroni’s Multiple Comparison Test (Prism).
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Figure 17. Peptide dendrimer SB105-A10 inhibits HMPV infection in human lung cells by
inhibiting binding.
(A) BEAS-2B cells treated with 1 µM SB105-A10 or vehicle were infected with rgHMPV or rgPIV5
at an MOI of 1. Cells were imaged at 24 hours post-infection. Percent infection of rgHMPV and
rgPIV5 at an MOI of 1 treated with variable concentrations of SB105-A10 in BEAS-2B (B) and A549
(C) cells was quantified using flow cytometry. The percent infection is reported normalized to the
untreated control for each virus type. Data points are means (+/- SD) of duplicate measurements
and are representative of a minimum of 3 independent experiments, * indicating statistical
significance P<0.0001. (D) HMPV viruses (WT and recombinant mutants ΔG and ΔGΔSH) were
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added to BEAS-2B cells treated with vehicle or with 1 µM SB105-A10 at an MOI of 1 at 4°C for
particle binding. Lysates of washed cells were analyzed for HMPV binding by Western blot analysis
for M. Input represents 5% of WT HMPV added to the cells for binding. No virus was added to
mock infected cells. β-actin served as a loading control. (E) Band intensities of the matrix protein
and β-actin were determined for untreated and treated (1 µM SB105-A10) samples. The data are
reported as a ratio of M to β-actin normalized to the untreated control for each virus. Data points
are means (+/- SD) of measurements representative of 5 independent experiments. * Indicates
statistical significance of P< 0.0002 using Bonferroni’s Multiple Comparison Test (Prism).
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Figure 18. Treatment of HAE tissues with SB105-A10 reduces HMPV infection.
(A) HAE tissues were treated with 2 µM SB105-A10 or vehicle (untreated) and infected with
rgHMPV at an MOI of 5. Tissues were imaged 48 HPI at 5X magnification. (B) Quantification of HAE
tissue infection. Data points are means (+/- SD) of triplicate measurements and are representative
of a minimum of 3 independent experiments.* Indicates statistical significance of P< 0.0001 using
Bonferroni’s Multiple Comparison Test (Prism).
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Figure 19. Model for inhibition of HMPV infection by interference between F and heparan
sulfate.
HMPV utilizes F for initial attachment to heparan sulfate found on the surface of target cells, with
potential involvement of an unidentified receptor necessary to complete entry. Sulfated
polysaccharides, iota- carrageenan and the heparan sulfate-like K5 polysaccharide derivatives,
inhibit this attachment step. Occluding heparan sulfate with SB105-A10 also blocks HMPV binding
by occluding HS from interaction with HMPV F.
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Chapter 5: Novel roles of HMPV G and SH during infection in bronchial epithelial cells
*These results were obtained with the help of Nicolás Cifuentes, who obtained images of WT and
recombinant HMPV particles using electron microscopy.
Introduction
HMPV is a ubiquitous pathogen that causes respiratory disease worldwide (28-30). First
identified in 2001 in the Netherlands, HMPV is now known to be the cause of respiratory
infections in humans since at least 1958 (31). Nearly every person is exposed to HMPV in the first
decade of life; sero-conversion occurs on average by the age of five and nearly 100% of individuals
test seropositive for antibody reactivity to HMPV antigens by age ten (7). HMPV is the second
most common cause of lower respiratory infection in children, following the closely related
respiratory syncytial virus (RSV) (37, 38). Importantly, up to 70% of infants hospitalized for severe
RSV bronchiolitis were also co-infected with HMPV, suggesting HMPV co-infection leads to more
severe disease during RSV infection (39-41). While infants are considered the most vulnerable
population to developing illness from HMPV, adults can foster severe respiratory infection as well,
especially elderly and immunocompromised patients (43-45).
Complications of respiratory infection associated with HMPV include pneumonia,
bronchiolitis, and febrile seizures (44, 59). Such complications can be life threatening in these
susceptible individuals. It has also been suggested that severe acute respiratory infection from
HMPV may have lifelong consequences such as asthma and hyperresponsiveness of the airway
(60, 61). While HMPV infection has been thought to be restricted to the respiratory epithelium
and lungs, there have been several reports of fatal encephalitis with HMPV the only detected
pathogen in both lung and brain tissue (62-64). Even though primary infection occurs during
childhood in the majority of cases, repeat infections are common throughout life, likely due to
strain variations and incomplete immunity. Despite HMPV prevalence and clinical relevance, there
are no specific antiviral treatments or vaccines available.
HMPV is an enveloped virus with a single-stranded, negative sense, non-segmented RNA
genome. It is a member of the paramyxovirus family, which includes RSV, measles virus, mumps
virus, and parainfluenza virus (PIV), in addition to the emerging zoonotic viruses of high mortality
in humans, Hendra and Nipah (356). Phylogenetic amino acid sequence analysis of HMPV isolates
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identified multiple strains and two major genetic lineages, A and B (30). In all isolates of HMPV to
date, three glycoproteins are present in the viral envelope: the fusion protein (F), the putative
attachment protein (G), and the small hydrophobic protein (SH) (90, 357). HMPV F mediates viral
membrane fusion and also plays a critical role in binding and infectivity (76, 77, 79). The roles for
HMPV G and SH are not as well understood, as they often differ in function from other viruses of
the same family.
In most paramyxoviruses the attachment protein typically interacts with a cell receptor
upon binding and triggers the fusion protein, which promotes subsequent fusion of viral and
cellular membranes. However, HMPV F is the primary factor for viral attachment in addition to its
role in membrane fusion. Recombinant HMPV without G was replication competent in cell culture
and in multiple animal models, although replication in the lower respiratory tract was modestly
attenuated (76, 77). Furthermore, some HMPV F proteins can promote cell-to-cell fusion with
acidic pH pulses, without co-expression of G (134, 136, 241-243). These findings suggest HMPV G
does not mediate the binding interaction that is typical of attachment proteins found in
paramyxoviruses.
In addition to HMPV, SH proteins are found in several other paramyxoviruses, including
members of rubulaviruses and pneumoviruses, and the unclassified J virus. The SH protein of
most paramyxoviruses is not required for viral replication in vitro (78, 358-360). The deletion of
the SH proteins of RSV and avian metapneumovirus (AMPV) reduced replication and
pathogenicity in animal models (80-82). However, recombinant HMPV lacking the SH gene was
found to replicate in both hamster and nonhuman primate models only marginally less efficiently
than wild-type (WT) HMPV (76, 83). While these findings suggest HMPV SH has a disposable role
in infection, all HMPV isolates to date have the SH gene, indicating its presence is required for
fitness (90). Several functions of HMPV SH have been identified recently. Like the SH of RSV (91),
the HMPV SH protein exhibits viroporin, or viral protein channel, activity (92). Furthermore, HMPV
SH can regulate the cell-to-cell fusion activity of F (92).
The roles of HMPV G and SH glycoproteins have been recently studied in more detail in
the context of HMPV entry. There is direct evidence the HMPV G and SH regulate HMPV entry,
which may contribute to immune system modulation of the host. Recent studies using
recombinant HMPV lacking G and SH showed that G and SH glycoproteins inhibit
macropinocytosis-mediated entry into human dendritic cells and reduce activation of CD4+ helper
T cells (93). Furthermore, it has been shown that HMPV G, specifically through the cytoplasmic
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tail domain, can disrupt mitochondrial signaling in airway epithelial cells that leads to an antiviral
response (361). Altogether, there is evidence that HMPV G and SH can affect virus uptake,
suggesting these glycoproteins affect F, which is the primary attachment for HMPV. However, the
mechanisms of the regulatory effects of G and SH in entry remain to be explored.
In this study, we utilized a model of human bronchial epithelial cells to characterize key
differences between WT HMPV and recombinant HMPV lacking G or both G and SH. The results
showed G and SH inhibit particle binding to human bronchial epithelial cells, as recombinant
HMPV ΔG and ΔGΔSH were able to bind more efficiently. However, heparan sulfate modulating
compounds inhibited the binding of the recombinant and WT HMPV similarly, supporting that F
mediates the critical interaction with heparan sulfate. Further analysis revealed increased binding
of the recombinant viruses did not result from great F incorporation in particles, and electron
microscopy did not reveal any significant differences in morphology between the recombinant
and WT HMPV. Interestingly, HMPV lacking G did not incorporate cellular actin into particles,
suggesting G may interact with the cell cytoskeleton during trafficking and assembly. These
findings demonstrate a potential novel role for HMPV G and further elucidate the complex,
regulatory interactions between viral proteins.
Results
Recombinant ΔG and ΔGΔSH HMPV bind BEAS-2B more efficiently than WT
We previously showed recombinant HMPV ΔG and ΔGΔSH purified by sucrose cushion
binds and infects Vero and CHO cell lines at WT levels (79). This purification process concentrates
viral participles of uniform density, which may exclude more variable forms of viruses that may
be budding. To better understand what role HMPV glycoproteins G and SH may have in HMPV
infection, we utilized human bronchial epithelial (BEAS-2B) cells infected by viruses purified using
SPG as a stabilizing agent and for cryoprotection, that does not exclude any particles. To
determine if G or SH affect particle binding, viruses purified by SPG were added to BEAS-2B cells
at 4°C, allowing for binding to occur but not infection, and the amount of bound virus was
quantified by analysis detection of the HMPV matrix protein present in cell lysates with β-actin as
a loading control, by Western blot. Five percent of input virus for each virus was also loaded for
comparison. Interestingly, HMPV ΔG and ΔGΔSH had greater binding to BEAS-2B cells than WT
HMPV (Fig. 20A and 20B) despite adding the same amount of virus (Fig. 20C). Quantification of
binding relative to input revealed enhanced binding of HMPV ΔGΔSH compared to WT HMPV,
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although HMPV ΔG also had a trend for increased binding (Fig. 20D). These results suggest G and
SH negatively regulate HMPV binding to BEAS-2B cells. To confirm that the enhanced binding
activity of recombinant viruses was still dependent on the interaction between F and heparan
sulfate, we utilized iota-carrageenan, a sulfated polysaccharide that has been shown to inhibit
HMPV binding and infection (Fig. 13). Pretreatment of WT HMPV and recombinant HMPV ΔG and
ΔGΔSH with 40 µg/mL of iota-carrageenan resulted in an inhibition of binding (Fig. 20A).
Furthermore, occlusion of heparan sulfate with 1 µM of peptide dendrimer SB105-A10 also
inhibited binding of WT HMPV and recombinant HMPV ΔG and ΔGΔSH (Fig. 20B). Taken together,
these results indicate the loss of G and SH results in increased binding to human bronchial
epithelial cells, and this binding is dependent on the interaction between F and heparan sulfate
as seen in WT HMPV.
We hypothesized that recombinant HMPV ΔG and ΔGΔSH incorporate more F into
particles due to the lack of one or both glycoproteins compared to WT HMPV. To test this, we
analyzed the relative content in WT and recombinant HMPV viruses of F compared to M (Fig. 21A).
Surprisingly, the recombinant HMPV ΔG or ΔGΔSH did not incorporate more F into the particles
(Fig. 21B), suggesting more F available for binding is not the mechanism of enhanced binding to
BEAS-2B cells.
The viruses used in these studies were purified using SPG, which does not select for
particles of uniform density the way concentrating sucrose purification does. It is possible the
recombinant HMPV lacking G or G and SH produces different shaped or sized particles than WT
HMPV that affect binding. To address this question, we performed electron microscopy on HMPV
ΔG (Fig. 22B) and HMPV ΔGΔSH (Fig. 22C), and compared particle appearance and size to WT
HMPV (Fig. 22A). Analysis of electron microscopy images did not reveal detectable differences in
particle shape as the WT (Fig. 22A) and recombinant HMPV (Fig. 22B and 22C) produced both
spherical and pleomorphic particles of variable size. Glycoprotein spikes were observed for WT
and recombinant viruses also (Fig. 22). Therefore, we were not able to identify any differences in
particle morphology to explain differences in binding, suggesting the glycoproteins G and SH may
regulate binding mediated by HMPV F.
Recombinant ΔG and ΔGΔSH HMPV do not incorporate cellular actin
In the binding assays using iota-carrageenan (Fig. 20A) and SB105-A10 (Fig. 20B), β-actin
was used as a loading control for cell lysates to ensure the same amount of protein was loaded in
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the untreated and untreated samples. Because the input virus samples were also analyzed within
the same gel, the amount of β-actin in the virus samples was also detected. Mass spectrometry
analysis of WT HMPV has shown cellular cytoskeletal proteins, such as β-actin, are found in
purified virus particles, presumably due to incorporation during particle assembly and budding (El
Najjar, et al., submitted). Interestingly, we noted WT HMPV incorporated small amounts of βactin, but there was no β-actin detected in samples of HMPV ΔG or HMPV ΔGΔSH (Fig. 20A and
20B). To confirm these observations, we analyzed the β-actin content of WT HMPV, recombinant
HMPV that results in green fluorescent protein expression (GFP) (rgHMPV), HMPV ΔG, and HMPV
ΔGΔSH by Western blot (Fig. 23A). M was also detected for comparison (Fig. 23A). While similar
amounts of M were detected for rgHMPV and the recombinant viruses (Fig. 23B), β-actin
incorporation in HMPV ΔG and HMPV ΔGΔSH was reduced compared to rgHMPV (Fig. 23C). These
results suggest HMPV G contributes to β-actin association with HMPV and possible incorporation
during assembly. However, what role, if any, recruitment of cellular actin into the viral particles
has in assembly and spread is unclear.
Discussion
HMPV F is essential and sufficient for infectivity. Recombinant HMPV without
glycoproteins G and SH is infectious in vitro and in vivo. However, all clinical isolates of HMPV
isolated to date contain genomes with all three glycoproteins, indicating that these proteins play
an essential role. The results presented here demonstrated HMPV G and SH can affect HMPV
binding to human bronchial epithelial cells, as recombinant viruses HMPV ΔG and HMPV ΔGΔSH
demonstrated enhanced binding compared to WT HMPV (Fig. 20). We concluded greater
incorporation of F (Fig. 21) or differences in particle morphology (Fig. 22) did not explain the
difference in particle binding.
It is possible that HMPV G may regulate binding by direct interaction with F, which is the
primary glycoprotein involved in attachment. While expression of HMPV F and M are sufficient
for virus-like particle (VLP) formation that resembles HMPV (362), G interacts with F in VLPs when
co-expressed with F and M (363). Furthermore, our group has shown SH can regulate cell-to-cellfusion activity of HMPV F expressed at the plasma membrane (92), further supporting a regulatory
role. It has been shown HMPV G and SH inhibit uptake by macropinocytosis in dendritic cells (93).
Therefore, HMPV G and SH may play a role in numerous aspects in F function: binding, fusion, and
mediating entry.
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While the results presented here demonstrated enhanced binding of HMPV ΔG and HMPV
ΔGΔSH compared to WT HMPV, our group has previously reported that the recombinant viruses
bind and infect Vero and CHO cell lines at WT levels (79). There are several possibilities to explain
different findings presented here. First, the viruses used in this study were prepared using SPG,
which serves as a stabilizing agent. This purification allowed for better preservation of the
diversity of viral particles, in contrast to purification by sucrose cushion which utilizes a density
barrier at high centrifugation speeds to concentrate particles of similar density and often results
in particle breakage. Therefore it is possible this methodology recovered a population of HMPV
ΔG and HMPV ΔGΔSH typically excluded by sucrose cushion purification, which allowed for the
observation of enhanced binding. Secondly, we utilized a respiratory bronchial epithelial cell line
to study the roles of G and SH in binding. BEAS-2B cells are non-cancerous, lung epithelial cells
that serve as a physiologically relevant model for respiratory virus infection. It is possible the
abundance of specific heparan sulfate proteoglycans (HSPGs) or integrin αVβ1, both of which
contribute to HMPV entry, differ in the airway cells than other cell types. Therefore, regulatory
effects of HMPV G and SH on F may become exposed when attachment factors are present in
different quantities or ratios. Lastly, it is possible that particle stability is reduced in HMPV ΔG and
HMPV ΔGΔSH, resulting in more defective particles that are unable to establish infection
compared to WT HMPV, although no significant differences were observed by electron
microscopy (Fig. 22). Such defective particles may still be able to bind to cells and be detected by
Western blot. Preliminary experiments to determine differences in infectivity did not reveal
enhanced infection in HMPV lacking G and/or SH compared to WT HMPV. However, further
studies are required to confirm this.
We showed HMPV lacking G, both HMPV ΔG and HMPV ΔGΔSH, was not associated with
cellular actin at levels comparable to that observed with WT HMPV (Fig. 20 and 23). There is no
current evidence of direct or indirect interaction of HMPV G with cellular actin. The actin
cytoskeleton, which is a central node in cellular pathways, is frequently targeted by various
pathogens to modulate cellular responses. The actin cytoskeleton has been shown to play a
critical role in the formation of filaments and cellular extensions that serve as HMPV assembly
sites and may contribute to cell-to-cell spread (El Najjar, et al., submitted). However, results
showed HMPV P induced the cytoskeletal changes, suggesting manipulation of the actin
cytoskeleton for spread and actin incorporation into HMPV particles may be unique functions of
distinct HMPV proteins. Furthermore, concentrated F-actin localizes to sites of HMPV filament
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budding in the plasma membrane and incorporates into filamentous particles (364). Incorporation
of cellular actin into particles has been reported for many viruses, including HIV-1 (365) , rabies
virus (366), and Newcastle Disease virus (367). For RSV, it is proposed that cellular actin is used as
a scaffold to propel filamentous viral to bud and leads to incorporation of cellular actin in the
particles (368). However, it is thought cytoplasmic tail of the RSV fusion protein is required for
the recruitment into filaments (369, 370). It is not known if the incorporation of cellular actin into
viral particles is deliberate and contributes to pathogenicity, or is simply a nuance of assembly.
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Figure 20. Recombinant HMPV ΔG and ΔGΔSH bind more efficiently to BEAS-2B cells than WT
HMPV.
(A) HMPV viruses (WT and recombinant mutants ΔG and ΔGΔSH) were treated with 40 µg/mL of
iota-carrageenan and added to BEAS-2B cells at an MOI of 1 at 4°C for particle binding. (B) HMPV
viruses (WT and recombinant mutants ΔG and ΔGΔSH) were added to BEAS-2B cells treated with
vehicle or with 1 µM SB105-A10 at an MOI of 1 at 4°C for particle binding. Lysates of washed cells
were analyzed for HMPV binding by Western blot analysis for M. Input represents 5% of WT HMPV
added to the cells for binding. No virus was added to mock infected cells. β-actin served as a
loading control. (C) Band intensities of the input M of WT and recombinant virus. Data points are
means (+/- SD) of measurements representative of 3 independent experiments. (D) Percent
bound particles compared to input of WT and recombinant HMPV, determined by quantification
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of M. Data points are means (+/- SD) of measurements representative of 5 independent
experiments. * Indicates statistical significance of P< 0.05.
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Figure 21. Recombinant HMPV ΔG and ΔGΔSH do not have greater F incorporation compared to
WT HMPV.
(A) Approximately 25,000 and 50,000 particles of WT HMPV, HMPV ΔG, and HMPV ΔGΔSH were
lysed, and proteins were separated by SDS-PAGE followed by Western blot analysis for F1 and M.
(B) Band intensities for F and M were quantified using ImageQuantTL, and the data are presented
as a relative ratio of F to M. (n=2)
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Figure 22. Electron microscopy imaging of viral particles.
(A) WT HMPV, (B) HMPV ΔG, and (C) HMPV ΔGΔSH were propagated in Vero cells for 4-5 days at
37°C and purified using SPG.
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Figure 23. Recombinant HMPV ΔG and ΔGΔSH are not associated with β-actin.
(A) Recombinant HMPV that results in GFP expression (rgHMPV), HMPV ΔG, HMPV ΔGΔSH, and
WT HMPV aliquots were lysed, and proteins were separated by SDS-PAGE, which was followed by
Western blot analysis for HMPV M and β-actin. (B) Band intensities for M and (C) β-actin were
quantified using ImageQuantTL, and the data are presented normalized to protein content in
rgHMPV. *Indicates statistically significant, P<0.05 (n=2).
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Chapter 6: HMPV Infection in a Cystic Fibrosis Model
Introduction
Cystic fibrosis (CF) is an autosomal recessive inherited disorder that affects many organ
systems of the body (371-373). Among Caucasians, it is the most common lethal genetic disease
with approximately 1 in 2,500 children born with CF in the United States (374). Approximately 1
in 25 Caucasians of European decent are carriers of the allele (375), likely due to heterozygous
advantage for the survival of Vibrio cholera infection (376, 377). CF is diagnosed by a sweat test
and genetic testing for known mutations commonly included in newborn screenings (378). The
average life expectancy of individuals with CF has risen to nearly 40 years, compared to only 16
years in the 1970s, due to do advances in treatments (379, 380). Cystic fibrosis is characterized by
disease in numerous organ systems, including exocrine pancreatic insufficiency, liver and kidney
dysfunction, malabsorption in the intestines, infertility in males, and chronic obstructive
pulmonary disease. However, complications due to lung dysfunction are responsible for death in
85% of people with CF (381, 382).
The basic genetic defect that causes this disorder, discovered over 25 years ago, resides
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (373). The resulting gene
product is a protein kinase A-activated chloride and bicarbonate selective ion channel involved in
salt and water transport across apical membranes of epithelial cells. It is expressed in secretory
and absorptive epithelial cells in the airway, pancreas, liver, intestine, sweat gland and the vas
deferens. CFTR also affects sodium transport through regulation of sodium channels at the plasma
membrane. Loss of CFTR function leads to defective anion secretion and sodium hyperabsoprion
across airway surfaces and submucosal glands. In the lungs, the resulting altered balance of ion
transport dehydrates the airway creating viscous mucus and impeding mucociliary clearance (379,
380, 383-386).
Many mutations in the CFTR gene have been identified that result in impaired CFTR
function, and a deletion of the 508th amino acid phenylalanine (ΔF508) is the most common,
accounting for about 70% of mutations that result in CF (383). CFTR ΔF508 in both copies of the
gene results in nearly a total absence of the channel in the membrane, as the misfolded mutant
protein fails to progress though the normal biosynthetic pathway from the endoplasmic reticulum
to the plasma membrane (387, 388). Other less common mutations, of which over 1,950 have
been identified, can result in lower expression CFTR or impaired CFTR function, often leading to
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less severe clinical presentation (389). Therefore, CF is a heterogeneous disease that ranges in
severity of organ dysfunction, although pulmonary dysfunction affects all individuals with this
disease.
The pathophysiology that results from CFTR dysfunction significantly impacts overall lung
function and greatly predisposes CF patients to lower respiratory tract disease. Without a proper
balance of ions at the apical surface of the airway epithelium, the airway surface liquid is depleted.
Retention of airway secretions leads to the hallmarks of CF lung disease, including chronic
bacterial airway infection, airway inflammation, and irreversible lung damage (384, 385, 390). The
clinical course of this disease is described by chronic inflammation which is punctuated by periods
of acute worsening of lung disease that increase with age and declining lung function, eventually
leading to lung transplantation or death (57). The most devastating bacterial culprit in CF patients
is Pseudomonas aeruginosa, as nearly 80% of CF patients are colonized during their lifetimes (391,
392). Once colonized, infection with P. aeruginosa becomes a chronic source of inflammation in
the lungs and is an indicator of poor prognosis (391, 392). It is thought that exacerbations in
airway disease occur due to an imbalance between chronic bacterial infection and host immune
response (393). Viral infection may be an important factor that triggers these events. Viral
respiratory tract infections are associated with exacerbations in children with CF (394, 395). In a
clinical study of viral infection in CF exacerbation, it was shown that virus infection was associated
with an increase in P. aeruginosa load (396).
Several viruses are well known to cause respiratory disease in CF patients, such as human
rhinovirus (HRV) (56, 397-400), parainfluenza virus 3 (397), adenovirus (56), influenza A (56, 399)
and respiratory syncytial virus (RSV) (398, 401). The impact of HMPV infection in CF patients has
not been addressed in detail. Few studies have examined the incidence and severity of respiratory
infection caused by HMPV in these patients. The limited studies that have assessed HMPV
infection in CF patients concluded that its prevalence rivals that of RSV and that HMPV is an
important clinical pathogen in this patient population (58, 402). In adults, one study found that
HMPV was second in prevalence after HRV for viral infection that caused acute exacerbation
(398). However, how HMPV infection may differ in the context of CFTR dysfunction compared to
healthy lungs is unknown.
Due to the limited knowledge regarding HMPV in the context of CF, we utilized a cystic
fibrosis bronchial epithelial (CFBE) cell line derived from a patient with the CFTR homozygous
ΔF508 mutation (403) as a model to study HMPV. Infection studies using HMPV and the related
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paramyxoviruses RSV and parainfluenza virus 5 (PIV5) revealed CFBE cells were more permissive
to specifically HMPV infection compared to other respiratory cell types, suggesting a unique hostvirus interaction. Furthermore, CFBE cells were entirely resistant to PIV5 infection. Heparan
sulfate modulating compounds that block HMPV binding in respiratory cells inhibited HMPV
infection in CFBE cells also, suggesting heparan sulfate serves as an attachment factor in these
cells. However, the increased infection of HMPV in CFBE cells could not be attributed to an
increase in overall virus binding. These findings suggest CFBE cells and possibly CF lungs are
specifically vulnerable to HMPV infection.
Results
CFBE cells more permissive to HMPV but not RSV infection than other human lung cells
Despite the prevalence of HMPV infection in the worldwide population, the impact of
HMPV has not been well characterized in patients with CF. The few existing studies have
suggested HMPV is a common cause of respiratory disease in these patients, detected at nearly
the same incidence as RSV. To examine HMPV infection in the context of CFTR dysfunction, we
utilized a cystic fibrosis bronchial epithelial (CFBE) cell line, which contains the most common
mutation in the CFTR gene, ΔF508, which leads to nearly a total lack of expression of the protein
product at the plasma membrane. To assess permissiveness of CFBE cells to HMPV infection,
infection at a specific multiplicity of infection (MOI) was compared to that observed in other
human lung cells, A549 and BEAS-2B, as well as Vero cells, which are monkey kidney epithelium
cells that lack interferon mediated signaling and are highly permissive to viral infection. The
experiments for each cell type were completed at equivalent passage numbers from thawing as
prolonged passaging can alter cellular protein expression and affect permissiveness to viral
infection. Vero, CFBE, A549 and BEAS-2B cells were cultured overnight, counted, and infected
with rgHMPV at MOI 0.1 and 0.5 and the percent of cells with green fluorescent protein (GFP)
expression was determined by flow cytometry 24 HPI. A similar efficiency of HMPV infection was
observed in A549 and BEAS-2B cells for each MOI, respectively (Fig. 24). As previously observed,
Vero cells demonstrated higher HMPV infection (Fig. 24). Interestingly, CFBE cells were similarly
permissive to HMPV infection as the Vero cells, and thus showed significantly higher infection
rates than both A549 and BEAS-2B cells (Fig. 24).
To determine if CFBE cells are highly permissive to other related respiratory viruses, all
four cell types were infected with rgRSV at MOI 0.1 and 0.5 and fluorescent cells were determined
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by flow cytometry 48 hours post infection, which is when GFP expression is highest in infected
cells. Unlike with HMPV infection, CFBE cells were the least permissive to RSV infection (Fig. 25).
A549 and BEAS-2B cells had similar levels of infection and Vero cells were the most permissive to
RSV infection (Fig. 25). These results suggest CFBE cells are selectively highly permissive to HMPV
compared to the closely related Pneumoviridae subfamily member, RSV.
CFBE cells are not permissive to PIV5 infection
Initial studies with paramyxoviruses in the Pneumoviridae subfamily, HMPV and RSV,
revealed CFBE cells were selectively permissive to HMPV infection compared to other human lung
cells. To determine if these cells promote higher infection of other paramyxoviruses, we analyzed
the efficiency of PIV5 infection in CFBE, A549, BEAS-2B, and Vero cells. All four cell types were
cultured overnight and infected with rgPIV5 at MOI1 and MOI5, and the percent of infected cells
was quantified by GFP expression using flow cytometry. Higher MOIs were used in these
experiments because no PIV5 infection was observed in CFBE cells in preliminary experiments
using MOI 0.1 and 0.5. Therefore, MOI was increased to determent if infection in these cells is
simply inefficient or if they were not permissive. Vero, A549 and BEAS-2B cells had similar
infection efficiency of PIV5 (Fig. 26). Surprisingly, CFBE cells were highly resistant to PIV5 (Fig. 26).
These results indicated viral infection is not enhanced in CFBE cells by a non-specific mechanism.
HMPV infection of CFBE cells inhibited by heparan sulfate modulation
HMPV has been shown to require to the proteoglycan heparan sulfate (HS) as a host
attachment factor to bind and infect cells (79). We have previously shown that nearly complete
reduction in binding and infection results when HS is removed from the cell surface using
heparinases, while cells that are able to synthesize only HS, and not any other GAGs, are fully able
to bind HMPV (79). Is it not known whether HS is required for HMPV binding in CFBE cells, or
whether increases in infection relate to increased binding either via HS or another host factor. To
test this, CFBE cells were treated with peptide dendrimer SB105-A10 (Fig. 12C), which specifically
occludes ligand binding from heparan sulfate proteoglycans (139, 350), and has been shown to
inhibit HMPV infection in non-CF human lung cells (Fig. 17). The resulting infection was quantified
by counting GFP-expressing cells by flow cytometry. HMPV infection was inhibited by
pretreatment of CFBE cells with SB105-A10 by nearly 75% (Fig. 27A), similar to inhibition observed
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in A549 (Fig. 17C) and BEAS-2B cells (Fig. 17B). These results suggest HMPV interaction with HS is
also required for infection in CFBE cells.
HMPV binding to HS can be inhibited by compounds that mimic HS (Fig. 15). K5
polysaccharide derivatives are heparan-like molecules devoid of anticoagulant activity obtained
by the sulfation of the E. coli capsular K5 polysaccharide that has the same structure as the
biosynthetic precursor of HS, N-acetyl heparosan. A small library of derivatives with different
degrees of sulfation has been synthesized using chemical and enzymatic modifications (318).
These HS modulating compounds inhibit HMPV infection in healthy bronchial epithelial cells (Fig.
15) and tissues (Fig. 16). To determine if HMPV infection can be inhibited by O-sulfated K5
derivatives in CFBE cells, CFBE cells were infected with HMPV pretreated with the K5
polysaccharide derivatives, and infection was quantified by counting GFP-expressing cells by flow
cytometry. As previously shown for BEAS-2B cells (Fig. 15B), the O-sulfated K5 derivatives
inhibited HMPV infection CFBE cells (Fig. 27B). Taken together, these results suggest HMPV
infection in CFBE cells did depend on interaction with HS as was observed for normal airway cells
and HS modulation is a potential antiviral strategy to prevent HMPV infection in CF patients also.
Enhanced HMPV infection is not a result of more particle binding
Greater HMPV infection was observed in CFBE cells compared to other cell types (Fig. 24).
This may be a result of increased particle binding or other more complex factors that affect virus
infection, such as transcription efficiency or protein trafficking during replication and assembly.
HMPV is known to bind HS to infect non-CF cells (79) and our results suggest HS is also a required
factor for HMPV infection in CFBE cells (Fig. 27). Increased sulfation and increased concentration
of glycosaminoglycans, including HS, have been shown in bronchi-alveolar fluid from children with
CF, compared to non-CF controls (404). Thus, it possible CFBE cells express more HS at the plasma
membrane, leading to greater HMPV binding and infection. To determine if CFBE cells bind HMPV
more efficiently than normal bronchial epithelial cells, HMPV was added to BEAS-2B or CFBE cells
at 4°C, allowing for binding to occur but not infection, and the amount of bound virus was
quantified by detection of the HMPV matrix protein present in cell lysates and β-actin as a loading
control, by Western blot. The detected bound protein was compared to the input. Surprisingly,
HMPV binding was about 3-fold less efficient in CFBE cells compared BEAS-2B cells (Fig. 28). Thus,
increased binding was not able to account for the greater infectivity observed in the CFBE cells.
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Discussion
A comparison of infection efficiency of HMPV, RSV, and PIV5 revealed selective increased
permissiveness in CFBE cells to HMPV infection (Fig. 24) and complete resistance to PIV5 infection
(Fig. 26). HMPV infection in CFBE cells did require HS (Fig. 27A) and was blocked by O-sulfated K5
polysaccharide derivatives (Fig. 27B). These results suggest loss of CFTR in the plasma membrane
results in a unique pathophysiology that primes CFBE cells to HMPV specifically.
It is not clear why HMPV infection is enhanced in CFBE cells compared to normal human
lung cells. It is possible that low pH contributes to HMPV infection in CBFE cells. The fusion protein
of HMPV carries out an essential step in viral infection to bind and fuse the viral envelope with
the target cells, and fusion proteins from many strains of HMPV can be triggered to fuse by low
pH (134, 136)(Fig ). The rgHMPV virus used in these studies is derived from strain CAN97-83 (A2)
and the F protein from this strain is triggered to fuse by low pH. It has been well documented that
the apical surface of the airway in CF lungs is acidic (405-407). CFTR itself functions as a chloride
and biocarbonate exchanger, and without CFTR, there is a decrease in bicarbonate efflux,
contributing to lower pH extracellularly. Furthermore, CFTR has a regulatory influence on the
adjacent Na+/H+ exchanger, resulting in suppression of its activity, thus reducing proton efflux. In
the absence of functional CFTR, as is the case in CF, proton efflux is not inhibited resulting in
further extracellular acidification. Therefore, it is possible the CFBE cells have an acidic
microenvironment that contributes to enhanced HMPV infection. Low pH does not trigger the
fusion proteins of RSV or PIV5 (222, 408, 409), providing a potential explanation of the increased
permissiveness to HMPV infection.
Calcium signaling can play a role in viral infection (410) and may also contribute to HMPV
infection (411). Unlike the matrix (M) proteins of other viruses, HMPV M has two calcium binding
sites (412), suggesting cellular calcium plays an important role in HMPV infection. CFBE cells have
an increased calcium concentration in the endoplasmic reticulum due to increased SERCA
(Sarcoplasmic/Reticulum Ca2+ ATPase) pump activity and decreased PMCA (Plasma Membrane
Ca2+ ATPase) activity (50). As a result, cytoplasmic calcium levels are lower in CFBE cells
compared to rescued cells with normal CFTR expression. It remains to be shown if lower
cytoplasmic calcium levels contribute to HMPV infection in CFBE cells. Furthermore, it is possible
CFBE cells upregulate other calcium transport mechanisms to reach calcium homeostasis, and
endocytosis is a means to increase calcium influx without PMCA activity, which is downregulated
in CF (413). There is direct evidence HMPV enters cells by endocytosis (136, 282), and increased
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endocytic uptake of calcium is a potential mechanism that allows for increased HMPV infection.
RSV infects cells via micropinocytosis (304) and PIV5 is thought to fuse at the plasma membrane,
both of which are entry mechanisms that would not be enhanced by endocytosis of calcium.
The CFBE cells were not permissible to PIV5 infection (Fig. 26). PIV5 requires sialic acid for
binding (414), and CFBE have been shown to have altered sialylation, which may contribute to the
resistance to infection. Decreased sialylation has been shown in CFBE cells (415). Furthermore,
sialic acid chains expressed on CFBE cells have significantly reduced terminal sialic acid in the
alpha-2,6 configuration (416). Viral specificity to bind alpha-2,6 sialic acid is a major determinant
of tropism (417-419). Clinically, viruses that utilize sialic acid for binding, such as Influenza A and
parainfluenza virus 3, have relatively low incidence of infection in CF patients compared to others
(56, 397-400). Therefore, the specific reduction in terminal sialic acid in the alpha-2,6
configuration of CFBE cells may be a contributor to viral tropism and infection in CF patients.
HMPV has only recently become recognized as a pathogen of clinical importance. While
it was discovered 15 years ago, there is evidence that HMPV has been causing respiratory disease
since at least 1948, though it was often clinically mistaken for RSV infection. Results presented
here suggest CFTR dysfunction specifically primes cells for HMPV infection, which has implications
for CF patients. While there is no vaccine or established effective treatment for HMPV infection,
it is important for clinicians to recognize HMPV may be a particularly important pathogen in this
patient group.
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Figure 24. HMPV infection in Vero and human lung cells.
Cells were infected with rgHMPV at MOI 0.1 or 0.5 in duplicate and the percent of infected cells
were determined by flow cytometry. Data points are means (+/- SD) of duplicate measurements,
*** indicates statistically significant, P<0.001 (n=3) using Bonferroni’s Multiple Comparison Test
(Prism).
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Figure 25. RSV infection in Vero and human lung cells.
Cells were infected with rgRSV at MOI 0.1 or 0.5 in duplicate and the percent of infected cells
were determined by flow cytometry. Data points are means (+/- SD) of duplicate measurements,
** and *** indicate statistically significant, P<0.01 and P<0.001, respectively (n=3), using
Bonferroni’s Multiple Comparison Test (Prism).
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Figure 26. PIV5 infection in Vero and human lung cells.
Cells were infected with rgPIV5 at MOI 1 or 5 in duplicate and the percent of infected cells were
determined by flow cytometry. Data points are means (+/- SD) of duplicate measurements (n=3).
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Figure 27. HS modulation inhibits HMPV infection in CFBE cells.
(A) CFBE cells were treated with SB105-A10 or vehicle for 1 hr at 37°C and infected with rgHMPV
at MOI 1. Infection was countrified by flow cytometry. Percent infection is reported normalized
to the untreated (0 nM). Data points are means (+/- SD) of duplicate measurements, * indicates
statistically significant, P<0.05 (N=3). (B) CFBE cells were infected with rgHMPV that was
pretreated with K5 polysaccharide derivatives (variable concentrations) or vehicle (untreated),
and infection was quantified by flow cytometry. Percent infection is reported normalized to the
untreated (0 nM). Data points are means (+/- SD) of duplicate measurements (n=2).
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Figure 28. HMPV binding is not more efficient in CFBE cells.
(A) HMPV was added to BEAS-2B and CFBE cells for 2 hr at 4°C at MOI 1 in triplicate. After
incubation, the cells were washed and lysed. Cell lysates were analyzed for HMPV matrix (M)
protein by Western blot and compared to input virus. (B) Quantification of Western blot results,
shown as percent bound M of input. * indicates statistically significant, P<0.05 (n=1).
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Chapter 7: Discussion and Future Directions
The body of work presented here contributes to our understanding of HMPV binding,
fusion, and infection in humans. These results in this thesis provide new insight into some of the
complexities of HMPV fusion protein function and characterized critical binding interactions.
Finally, the work described has direct translational ramifications. Characterization of HMPV
infection in cystic fibrosis revealed a potential vulnerability of this patient group to this pathogen.
Taken together, these findings elucidate key features of the HMPV viral cycle, provide a
foundation for antiviral development, and identify a vulnerable clinical population.
Complexity of fusion protein regulation and implications of acidic pH promoted fusion
Prior to the work in this thesis, a total of five HMPV F proteins had been analyzed for pH
requirements to promote fusion (134, 136, 241, 242), and only CAN97-83 (A2) F has been
characterized to be independent of its associated G protein (134), while the others were not
evaluated for fusion activity in the presence of HMPV G. Cumulatively, low pH dependence, low
pH independence, and failure to promote cell-to-cell fusion were all documented for different
HMPV F proteins. Site directed mutagenesis at specific residues resulted in loss of fusion activity
or changes from low pH dependence to independence, or vice versa. These results led to a
hypothesis that low pH promoted fusion among HMPV F proteins is rare, unique to certain clade
A, and requires the presence of specific residues, such as glycine 294 (241, 242). However, the
results shown here demonstrate that HMPV F requirements for acidic pH are more complex
(Chapter 3). We demonstrated cell-to-cell fusion promoted by TN83-1211 (B2) F and TN94-49
(A2), which does not have a glycine at position 294, can be triggered by low pH. These results
demonstrate the challenges of understanding what contributes to low pH triggered fusion and its
significance among all HMPV strains. Furthermore, two HMPV F proteins, from TN96-12 (A1) and
NL/17/100 (A2) (241, 242), have been identified that fail to promote cell-to-cell fusion when
expressed at the plasma membrane. However, both virus strains are capable of establishing
productive infection (241, 242, 282), which suggests these F proteins require either additional
viral factors, such as HMPV G or HMPV SH, or additional cellular factors, such as a specific receptor
factor or unique lipid membrane composition available only in certain compartments (420), that
are not present when the F proteins are expressed at the plasma membrane to promote fusion.
These factors may regulate HMPV F activity through a number of potential mechanisms, and
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acidic pH may still contribute to the triggering of these proteins, but is not sufficient when F is the
only viral protein expressed at the plasma membrane. Because we are not able to determine if
the HMPV F proteins that failed to promote cell-to-cell fusion were in the metastable prefusion
conformation or the postfusion conformation, it is not clear if they require a stabilizing or
triggering factor. The presence of an additional viral protein may contribute to either stabilizing
the F protein to prevent premature triggering, or contribute to the triggering of the F protein. We
plan to determine if HMPV G promotes cell-to-cell fusion of the HMPV F proteins analyzed in this
thesis as a starting point to determine if G is required for other HMPV F.
Until recently, there was a simple, binary understanding of viral fusion and entry that was
linked by the pH of fusion protein triggering. It was thought viruses with fusion proteins that are
triggered independent of pH, at neutral pH, bind cell surface receptors and fuse the viral
membrane with the plasma membrane (421). Viruses belonging to the Retroviridae,
Paramyxoviridae, Herpesviridae, and Coronaviridae families typically initiate fusion in a pHindependent manner (215). On the other hand viruses with fusion proteins that can be triggered
by exposure to acidic pH were thought to bind cell surface receptors and be taken up by
endocytosis, where exposure to acidic pH in the maturing endosome would provide the necessary
trigger to promote the fusion protein activity (421). Viruses belonging to the Orthomyxoviridae,
Togaviridae, Rhabdoviridae, Bunyaviridae, and Arenaviridae families typically require a low-pHmediated event for efficient fusion of viral and host cellular membranes (215). Because the fusion
proteins of most paramyxoviruses to date can be triggered independently of pH, the entire
Paramyxoviridae family of viruses was previously thought to fuse at the plasma membrane (421).
However, this association has been challenged with our group’s identification for the role of low
pH in HMPV fusion protein activity (134, 136) as well as recent reports of more complex routes of
entry for several viruses in the family. RSV can enter cells by macropinocytosis (304) and evidence
suggests that New Castle Disease virus is taken up by endocytosis (286, 287). Recent studies also
indicate that HMPV fusion can take place in endosomal compartments (282) after complex entry
mediated in a dynamin- and clathrin- dependent endocytosis (136, 282). These findings have
provided a biological context for the acidic pH to trigger HMPV F. Cox et al. reported that
prototype strains in each clade (A1, A2, B1, B2) utilize endocytosis, however infection of only some
strains was modestly inhibited by chemical interference of endosomal acidification (282).
Interestingly, some of the same strains were used in these entry studies that we used to
characterize fusion protein activity in Chapter 3. Treatment of cells with ammonium chloride, a
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weak base that blocks vacuolar acidification, resulted in as much as a 50% reduction in infection
of the A2 virus, which is TN94-49. Our analysis of TN94-49 F revealed acidic pH can promote the
fusion activity of this HMPV F. However, ammonium chloride treatment failed to inhibit infection
of the A1 virus, TN96-12. Low pH is insufficient to trigger the fusion activity of TN96-12 F,
suggesting other factors are required which have not yet been identified. (We do not have
information regarding the fusion proteins of the B1 and B2 viruses used in the endocytosis
studies.) Therefore, there may be a correlation between low pH trigger during endocytosis and
low pH promoted fusion in cell based assays that isolate the fusion protein. However, more
complex regulation may be at play in the case of HMPV, than some other low pH-triggered viruses,
such as VSV and influenza A, which can be completely blocked by ammonium chloride treatment
(282, 315, 422, 423). Of the strains that have been analyzed, all HMPV particles require
endocytosis to infect bronchial epithelial cells (282), however not all of the F proteins require low
pH for fusion and infection of only some strains is inhibited by blocking acidification. Taken
together, this suggests HMPV particles may escape the maturing endosome into the cytosol at
different times depending on the requirement for low pH. Following endocytosis and pinching off
the membrane, the endosomes travel towards the nucleus while the pH begins to decrease (424).
Depending on pH requirements of the fusion protein of that virus particle, it is possible fusion can
occur anywhere from early endosomes to endosomes. However, there is an advantage to viral
escape in late endosomes closer to the nucleus, as this delays the antiviral response of the cell
and has been shown to promote viral infection for other viruses that utilize endocytosis for entry.
Furthermore, preliminary imaging of HMPV replication bodies has shown perinuclear localization.
Other HMPV glycoproteins, G and SH, may have more of a regulatory activity role in F
activity than initially hypothesized from animal studies using recombinant HMPV lacking one or
both of these proteins, as the strain employed in those studies utilized a low pH triggered F. Thus,
the biological requirement for low pH in HMPV may vary depending on the interactions between
the unique glycoproteins present in each strain of this virus. We hypothesize HMPV strains with F
proteins that function independently from their complementary G may be more dependent on
acidic pH to trigger fusion to escape the endosome, whereas those that require additional viral or
cellular factors, such as TN96-12 (A2) F, not depend on acidic pH in the endosome to facilitate
fusion. Whether this hypothesis holds true for HMPV entry remains to be determined.
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Heparan sulfate proteoglycans as a potential receptor for HMPV
Heparan sulfate has been identified as a receptor for numerous viruses, whereas the
other glycosaminoglycans are rarely implicated in virus-host interactions. HS is the most
negatively charged due to the addition of sulfate groups, which has led to a hypothesis that
nonspecific charge-charge interactions drive the attraction between diverse viral proteins and the
sulfated polysaccharide on the surface of cells. However, our findings that O-sulfation is required
to compete with HMVP binding to HS, suggest this is not entirely a simple charge interaction.
Furthermore, it has been shown RSV has entirely different sulfation requirements for binding to
HS, as N-sulfation is required while O-sulfation is dispensible (425). Thus, although a number of
different viruses bind HS, likely due to prevalence of expression among mammalian tissues, they
may not share the same mechanism mediating this interaction.
HS is found mainly on two families of cell surface proteins: syndecans and glypicans, and
thus it is possible that a specific protein in one of these families may serve as a receptor for HMPV.
Glypicans had not previously been identified as a receptor for a human virus until recently, when
it was shown GPC-5 serves as a receptor for hepatitis B and hepatitis D viruses (204). Syndecans,
on the other hand, have been identified to serve as an attachment factor for numerous viruses
that bind HS. SDC-1 has been identified as an attachment factor for hepatitis C (172). SDC-2 and
SDC-3 have been identified as receptors for Dengue virus (168) and HIV-1 (161), respectively.
Because the different syndecan proteins are expressed in a cell-specific and tissue-specific
manner, SDC-1 and SDC-4 are more likely to serve as an attachment factor for a respiratory virus
due to their abundance in bronchial epithelial cells, among other tissues. On the other hand, SDC2 and SDC-3 are enriched in the thymus and neurological tissues. Due to its expression in the
human airway, SDC-1 serves a potential receptor or coreceptor HMPV. Anti-SDC-1 antibodies have
shown to reduce RSV infection at the apical surface of HAE tissues (355). This is an approach that
could be used to determine if SDC-1 also is specific for HMPV binding. SDC-4 is also a potential
receptor for HMPV, based on its tissue expression and roles in endocytosis and integrin recycling.
Ligand binding to SDC-4 has been shown to orchestrate the activation of GTPases to initiate
endocytosis in a dynamin-dependent manner and recycling of α5β1-integrin (426). SDC-4 has been
associated with cell-extracellular matrix junctions, suggesting these HSPGs may not be readily
available for interaction with a virus particle.
In apical infection of HAE tissues, a critical step in the preparation of the tissues for
infection was washes using lysophosphatidic choline (LPC). LPC is a complex, inverted cone96

shaped lipid naturally found in plasma membranes and as a pulmonary surfactant in low
quantities (427, 428). LPC washes prior to HAE infection have been used for a number of viruses,
and were first used for HMPV by another group (320). Without LPC, HMPV infection is delayed
and less efficient in tissues. In vivo, LPC enhanced infection of adenovirus was observed in mouse
(429), rabbit (430) and baboon lungs (431), acting as an adjuvant to increase lentivirus gene
expression (432, 433). Treatment with LPC results in a decrease or loss of trans-epithelial
resistance, potentially by disrupting cell-to-cell junctions (434). Taken together, this suggests LPC
increases virus access to the airway cell surface receptors, which may only be available for binding
at the apical surface at low levels prior to LPC treatment. Furthermore, transient disturbance of
the epithelial barrier function may permit virus access to basolateral receptors or basal cells not
normally exposed. For HMPV, apical infection of HAE tissues is enhanced by LPC, but apical
infection can still occur without LPC washes of the apical surface. Even with LPC treatment, HMPV
infection is primarily limited to the apical layer of HAE tissues. This suggests the required receptors
are present at low numbers at the apical surface and disruption of the integrity of the epithelium
with LPC increases their availability for binding, leading to greater efficiency of infection.
Sulfated polysaccharides as an antiviral strategy
Our results demonstrate the efficacy of sulfated polysaccharides to block binding and
inhibit infection of HMPV. We propose such compounds may serve as a platform for antiviral
development. Sulfated derivatives have been previously employed as an antiviral strategy in
humans with limited success. Sulfated polysaccharides were first applied clinically to prevent
infection of sexually transmitted viruses, such as HIV-1, HSV, and HPV. The phase III clinical trial
for carrageenan-based Carraguard showed it did not reduce the risk of HIV infection (435, 436).
However, Carraguard has been shown to protect women against high risk-HPV infection (437).
Furthermore, carrageenan-based microbicides also appear to be promising to protect against
HSV-2 infection (438). Therefore, carrageenan-based antivirals show great potential for clinical
value.
Iota-carrageenan has been safely delivered in humans as a nasal spray to reduce viral
infection in several clinical trials (341). Although the results did not demonstrate a reduction in
symptoms or duration of illness, the delivery was limited to nasal epithelium and subjects began
using the carrageenan spray only after experiencing the onset of symptoms. Therefore, it is likely
viral infection had already spread to the upper respiratory tract beyond the nasal respiratory
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epithelium. However, reduction in viral titer was observed in the treatment group, suggesting
iota-carrageenan was efficacious to reduce viral replication. We propose such an antiviral strategy
would be most effective as prophylaxis, before the onset of respiratory symptoms. While this
would not be a practical approach for most individuals, those at risk to severe illness from HMPV
may benefit greatly. This includes patients in elderly care facilities, hospitals, as well as
immunocompromised patients, such as bone marrow or organ transplant recipients.
Furthermore, aerosolized delivery of a sulfated polysaccharide such as iota-carrageenan would
increase delivery to the lower respiratory tract. Thus, treatment of at-risk patients experiencing
symptoms of upper respiratory tract infect may prevent the spread of virus to the lower airway,
which is the main contributor of morbidity and mortality due to respiratory infection. Treatment
with sulfated polysaccharides could protect at risk patients not only from HMPV infection, but
potentially other respiratory viruses that utilize heparan sulfate for binding, including RSV (163,
176, 425), the leading cause of respiratory infection in children. Currently, there are no approved
vaccines for either RSV or HMPV. Furthermore, high-risk premature infants receive monoclonal
antibody therapy as prophylaxis for RSV infection, which is both costly and does not have
established efficacy in clinical settings outside of controlled trials (439, 440), where the efficacy
of palivizumab has been shown (441). Therefore, there are multiple patient groups that would
benefit from a prophylactic therapy to reduce HMPV and RSV infection. Furthermore, iotacarrageenan has shown efficacy to inhibit influenza A (338) and rhinovirus infection (354).
Although our results suggest individuals with cystic fibrosis would benefit from HMPV
prophylaxis, the consequences of sulfated polysaccharide delivery to upper or lower respiratory
tract in these patients may propose unique risks. Sulfated polysaccharides contribute to chronic
colonization and antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis patients.
Heparan sulfate inhibits the killing of P. aeruginosa (442), possibly because heparan sulfate is
incorporated in biofilms that protect the bacterial pathogen (384, 391, 394). However, other
formulations may circumvent some of the unique challenges posed by introducing
polysaccharides to cystic fibrosis lungs. Sulfated polysaccharides have been delivered in liposomes
with efficacy to inhibit replication of some respiratory viruses (443). Thus, further studies are
necessary, perhaps in the swine animal model of cystic fibrosis, to determine if sulfated
polysaccharides would reduce viral infection or simply contribute to P. aeruginosa colonization.
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The role of HMPV G in cellular actin recruitment
Cellular actin is often detected inside or associated with viral particles, suggesting it is
packed during assembly. Incorporation of cellular actin into particles has been reported for many
viruses, including HIV-1 (365) , rabies virus (366), and Newcastle Disease virus (367). For RSV, βactin and number of actin-related proteins have been found in the same sucrose gradient-purified
fractions as RSV particles (444, 445), which has led to the hypothesis that cellular actin is used as
a scaffold to propel filamentous viral to bud (368). However, RSV filament analysis for presence
of actin associated proteins in the particles did not shown incorporation of the proteins examined,
although they were not analyzed for β-actin content (370). Numerous proteins of the actin
cytoskeleton were find by mass spectrometry analysis of ultra-purified WT HMPV particles (El
Najjar, et al., submitted). There are sufficient levels of β-actin present that it be visualize be
Western blot analysis of virus samples. It was somewhat of an incidental finding when we
observed no β-actin is present in samples of HMPV ΔG or HMPV ΔGΔSH. These findings are still
preliminary and further analysis is required to determine if this has any significant in infection or
viral fitness. Recent work by Farah El Najjar has highlighted the role of the actin cytoskeleton in
formation of cellular filaments and extensions thought to function as a mechanism of cell-to-cell
spread. Thus, HMPV G may play a role in driving or regulating some of these processes. Previous
studies with the recombinant HMPV ΔG or HMPV ΔGΔSH in both in vivo and in vitro models have
emphasized that they function similarly to WT HMPV, leading to questions about the roles of
these additional proteins. The work presented here, both in regulation of binding and effects in
actin incorporation, brings to attention some of the fine tuning these proteins may do during
HMPV infection and essentially preserve their own necessity among HMPV viruses. Subtle effects
on mediating binding, fusion, entry, particle assembly, and immune modulation under
experimental conditions may translate to substantial advantages to maintain fitness in the
population.
HMPV infection in cystic fibrosis
Our results showed a cystic fibrosis bronchial epithelial cell line had greater
permissiveness to HMPV infection than RSV or PIV5. These findings suggest the loss of CFTR
expression in the plasma membrane results in cellular changes that specifically enhance HMPV
infection in vitro. To determine that it is the specific loss of CFTR expression that contributes to
HMPV infectivity in this cell line, utilization of a cell line that has rescued CFTR should be explored.
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We would expect to see a decrease in HMPV infection in these cells compared to the native CFBE
cells. Furthermore, we can use silencing RNA approaches to known-down CFTR expression in
healthy human bronchial epithelial cells to determine if HMPV infection is enhanced. Several
hypotheses are discussed in Chapter 6 for potential mechanisms of increased HMPV infection,
including acidic microenvironments, calcium dysregulation and uptake, and increased expression
of HSPGs. Additionally, there is evidence loss of CFTR leads to deregulation of the actin
cytoskeleton (446). HMPV utilizes the actin cytoskeleton to promote egress and spread (El Najjar,
submitted). It is possible that actin cytoskeleton deregulation in CFBE cells contributes to more
efficient HMPV infection.
While our results suggested increased binding was not the mechanism of increased
infectivity in CFBE cells compared to normal bronchial epithelial cells, it is not clear what the
mechanism of increased infectivity may be. We plan to examine replication of HMPV in CFBE cells
using a novel technique developed by Nicolás Cifuentes to visualize replication bodies using
fluorescent in situ hybridization (FISH) to detect viral genomes and messenger RNA transcripts.
HMPV infection in BEAS-2B cells results in formation of perinuclear replication bodies where viral
genomes are being replicated and transcribed (unpublished data). These replication bodies vary
in size and number, from one to several per cell, and can travel between cells through intercellular
extensions (unpublished data). It is possible HMPV genome transcription and replication is more
efficient in CFBE cells, which may result in detection of replication bodies at earlier time points
post-infection, more replication bodies per cell, or larger replication bodies. It also remains to be
determined if HMPV may replicate to higher titers in CFBE cells.
The studies in CFBE cells were done with a recombinant virus that results in GFP
expression that is based on strain CAN97-83 (A2). It is not know at this time if CFBE permissiveness
will be observed to other strains of HMPV. Furthermore, the fusion protein of CAN97-83 can be
promoted to fuse by acidic pH. It is not known what role this may have in enhanced infection in
CFBE cells, which have acidic pH at the plasma membrane. Additionally, one of the
paramyxoviruses used in these studies, PIV5, does not cause not cause disease in humans,
although most individuals have antibodies to this virus (18). However, it typically infects human
cell lines efficiently, which contributed to the unexpected findings in CFBE cells. Thus, it would
contribute to our understanding of viral infection in cystic fibrosis to additionally characterize
other viruses commonly linked to cystic fibrosis exacerbation, including HRV, parainfluenza
viruses 1 and 3, and influenza A. We hypothesize alteration in terminal sialic acid composition
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results in resistance to PIV5 infection in CFBE cells, which could have implications for other sialic
acid- binding viruses in endogenous infection in these patients.
HMPV propagation in vitro and future analysis of clinical strains
RNA viruses rapidly adapt to the available host environment, often due to error prone
polymerases that lack proof-reading mechanisms. As a result, in vitro propagation of RNA viruses
originally isolated from ill patients may result in changes that promote efficient growth and
replication in immortalized cells. We have identified critical virus-host interactions using primarily
HMPV strain CAN97-83, one of the best characterized strains of HMPV. In order to broaden the
understanding of HMPV life cycle and identify any strain-to-strain differences, we plan to
incorporate not only additional strains, some of which have been already noted in this
dissertation, but also new clinical isolates of HMPV from sick children at the University of Kentucky
Children’s Hospital. To date, we have confirmed the presence of HMPV in 15 clinical isolates.
Future studies with these novel strains include sequence analysis of genomes, characterization of
dependency of HS for binding, and efficacy of apical infection in HAE tissues.
Conclusion
This body of work contributes to our understanding of the life cycle of HMPV. We
characterized critical aspects HMPV F protein triggering by low pH, which has biological relevance
for endocytic entry. Analysis of F proteins from phylogenetically diverse HMPV strains
demonstrated low pH triggered fusion, challenging previously thought requirements, and led to
the identification of a critical residue that enhances low pH promoted fusion. These results
support our hypothesis that electrostatic interactions play a key role in HMPV F triggering by low
pH and further elucidate the complexity of viral fusion proteins. We characterized the key features
of the binding interaction between HMPV and HSPGs using heparan sulfate mimetics, identifying
an important sulfate modification, and demonstrate that these interactions occur at the apical
surface of polarize airways tissues. These results significantly advance our understanding of HMPV
infection in the human airway and identify an antiviral strategy. Furthermore, in our analysis of
HMPV F mediated binding to HSPGs, we identified regulatory roles of HMPV glycoproteins G and
SH that affect binding mediated by F and a potential novel function for HMPV G in actin
recruitment. These results contribute to our understanding of the HMPV G and SH, which often
do not share the same functional roles of analogous proteins found in viruses of the same family.
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Furthermore, our results identified a potential specific susceptibility to HMPV infection in cystic
fibrosis cells, which has not been previously reported. Therefore, the work presented here
contributes to our understanding of HMPV infection over a broad breadth, from mechanisms of
early events of entry to a clinical model of chronic respiratory disease.

102

Appendix I: Abbreviations Used in this Document
6-HB

Six-helix bundle

AMPV
ATCC

Avian metapneumovirus
American Type Culture Collection

CF

Cystic fibrosis

CFBE
CFTR
ER

Cystic fibrosis bronchial epithelium
Cystic fibrosis conductance regulator
Endoplasmic Reticulum

F

Fusion

FBS

Fetal Bovine Serum

FP

Fusion peptide

GAG

Glycosaminoglycan

GFP

Green fluorescent protein

GPI

Glycophosphatidylinositol

HAE
HeV

Human airway epithelium
Hendra virus

HEV

Hepatitis E virus

HIV

Human immunodeficiency virus

HMPV

Human metapneumovirus

HN/G/H

Paramyxovirus attachment protein

HPI
HPIV1

Hours post-infection
Human parainfluenza virus 1

HPV
HRA

Human papilloma virus
Heptad repeat A

HRB

Heptad repeat B

HRV
HS

Human rhinovirus
Heparan sulfate

HSPG

Heparan sulfate proteoglycans

HSV-1

Herpes simplex virus 1

HTLV-1

Human T-cell leukemia virus 1

M
MeV

Matrix protein
Measles virus

MOI

Multiplicity of infection

MTT

(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
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NiV

Nipah virus

P
P/S

Phosphoprotein
Penicillin/Streptomycin

PAGE

Polyacrylamide gel electrophoresis

PI3K

Phosphoinositide 3 – kinase

PIV3

Parainfluenza virus 3

PIV5

Parainfluenza virus 5

PKC

Protein kinase C

PMCA
PVDF
RSV

Plasma membrane calcium ATPase
Polyvinylidene flouride
Respiratory Syncytial virus

SDC

Syndecan

SERCA
SeV

Sarco/endoplasmic reticulum calcium ATPase
Sendai virus

SH
SPG
TM

Small hydrophobic protein
Sucrose phosphate glutamate
Transmembrane domain

VLP

Virus-like particle

VSV

Vesicular stomatitis virus

WT

Wild type
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